<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1920_S07_C17IDX_p339_358_8P</title>
		<link href="BCSC1920_S07_C17IDX_p339_358_8P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1920_S07_C17IDX_p339_358_8P" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="endmatter-title ParaOverride-1">Index</p>
			<p class="em-only_endmatter-idx1">(<span class="endmatter-idx1_italic">f</span> <span class="endmatter-idx1_symbol">=</span> figure; <span class="endmatter-idx1_italic">t</span> <span class="endmatter-idx1_symbol">=</span> &#173;table)</p>
			<p class="endmatter-idx1 ParaOverride-2">A-&#173;scan ultrasonography, 31</p>
			<p class="endmatter-idx1">AAPOX. <span class="endmatter-idx1_italic">See</span> Adult-&#173;onset asthma with periocular xanthogranuloma</p>
			<p class="endmatter-idx1">Abducens nerve</p>
			<p class="endmatter-idx2">anatomy of, 13<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">extraocular muscle innervation by, 12</p>
			<p class="endmatter-idx1">AbobotulinumtoxinA, 269</p>
			<p class="endmatter-idx1">ACC.&#160;<span class="endmatter-idx1_italic">See</span> Adenoid cystic carcinoma</p>
			<p class="endmatter-idx1">ACE.&#160;<span class="endmatter-idx1_italic">See</span> Angiotensin-&#173;converting enzyme</p>
			<p class="endmatter-idx1">Acquired aponeurotic ptosis, 245, 245<span class="endmatter-idx1_italic">t</span>, 245<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Acquired distichiasis, 170</p>
			<p class="endmatter-idx1">Acquired myogenic ptosis, 245</p>
			<p class="endmatter-idx1">Acrocephalosyndactyly, 39, 39<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Acropachy, 58</p>
			<p class="endmatter-idx1">Actinic keratosis, 198–199, 199<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Actinomyces israelii,</span> 305, 313</p>
			<p class="endmatter-idx1">Acute dacryocystitis, 313–314</p>
			<p class="endmatter-idx1">Acute spastic entropion, 237</p>
			<p class="endmatter-idx1">Adenocarcinoma, of paranasal sinuses, 102</p>
			<p class="endmatter-idx1">Adenoid cystic carcinoma (ACC), 100</p>
			<p class="endmatter-idx1">Adenoma</p>
			<p class="endmatter-idx2">pleomorphic, 98–100, 99<span class="endmatter-idx2_italic">f</span>, 192</p>
			<p class="endmatter-idx2">sebaceous, 191</p>
			<p class="endmatter-idx1">Adits, 274</p>
			<p class="endmatter-idx1">Adult-&#173;onset asthma with periocular xanthogranuloma (AAPOX), 97</p>
			<p class="endmatter-idx1">Adult-&#173;onset xanthogranuloma (AOX), 97</p>
			<p class="endmatter-idx1">Afferent pupillary defect, 119</p>
			<p class="endmatter-idx1">Aging face</p>
			<p class="endmatter-idx2">pathogenesis of, 267</p>
			<p class="endmatter-idx2">physical examination of, 267–268</p>
			<p class="endmatter-idx2">rejuvenation techniques for. <span class="endmatter-idx2_italic">See</span> Facial rejuvenation</p>
			<p class="endmatter-idx1">AIDS, 211</p>
			<p class="endmatter-idx1">Air cells, ethmoid sinus, 20</p>
			<p class="endmatter-idx1">Albright syndrome, 89</p>
			<p class="endmatter-idx1">Allergic aspergillosis, 52</p>
			<p class="endmatter-idx1">Allogenic slings, 252</p>
			<p class="endmatter-idx1">Alloplastic orbital implants, 117</p>
			<p class="endmatter-idx1">Alveolar rhabdomyosarcomas, 88</p>
			<p class="endmatter-idx1">Amblyopia, 180, 243</p>
			<p class="endmatter-idx1">American Society of Ocularists, 141</p>
			<p class="endmatter-idx1">Ampullectomy, 311</p>
			<p class="endmatter-idx1">ANCA serum assay. <span class="endmatter-idx1_italic">See</span> Antineutrophil cytoplasmic autoantibody (ANCA) serum assay</p>
			<p class="endmatter-idx1">Angiotensin-&#173;converting enzyme (ACE), <br />34, 66</p>
			<p class="endmatter-idx1">Ankyloblepharon, 175–176, 176–177<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Ankyloblepharon filiform adnatum, 175</p>
			<p class="endmatter-idx1">Annulus of Zinn, 11, 13<span class="endmatter-idx1_italic">f</span>, 13–14, 164</p>
			<p class="endmatter-idx1">Anophthalmia</p>
			<p class="endmatter-idx2">congenital, 136</p>
			<p class="endmatter-idx2">consecutive, 35</p>
			<p class="endmatter-idx2">definition of, 35</p>
			<p class="endmatter-idx2">primary, 35</p>
			<p class="endmatter-idx2">secondary, 35</p>
			<p class="endmatter-idx2">treatment of, 36–38</p>
			<p class="endmatter-idx1">Anophthalmic ectropion, 144, 144<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Anophthalmic ptosis, 145, 145<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Anophthalmic socket surgery</p>
			<p class="endmatter-idx2">complications of</p>
			<p class="endmatter-idx3">anophthalmic ectropion, 144, 144<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">anophthalmic ptosis, 145, 145<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">conjunctival cyst, 141, 141<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">contracted fornices, 143</p>
			<p class="endmatter-idx3">contracted sockets, 143–144, 144<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">cosmetic optics, 145–146</p>
			<p class="endmatter-idx3">deep superior sulcus, 141, 141<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">&#173;giant papillary conjunctivitis, <br />142, 142<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">lash margin entropion, 145, 145<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">enucleation. <span class="endmatter-idx2_italic">See</span> Enucleation</p>
			<p class="endmatter-idx2">evisceration. <span class="endmatter-idx2_italic">See</span> Evisceration</p>
			<p class="endmatter-idx2">goals of, 135</p>
			<p class="endmatter-idx2">indications for, 135</p>
			<p class="endmatter-idx2">orbital implants</p>
			<p class="endmatter-idx3">description of, 117, 139<span class="endmatter-idx3_italic">f</span>, 139–141</p>
			<p class="endmatter-idx3">exposure and extrusion of, 142<span class="endmatter-idx3_italic">f</span>, 142–143</p>
			<p class="endmatter-idx2">prostheses, 140–141, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Anterior clinoid pro&#173;cess, 8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Anterior cranial fossa, 8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Anterior ethmoidal artery, 9</p>
			<p class="endmatter-idx1">Anterior ethmoidal foramen, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Anterior lamella</p>
			<p class="endmatter-idx2">cicatrix of, 217<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">upper eyelid defects, 220</p>
			<p class="endmatter-idx1">Anterior lamellar deficiency, 254</p>
			<p class="endmatter-idx1">Anterior orbitotomy approach, 87. <span class="endmatter-idx1_italic">See also</span> <br />Orbitotomy</p>
			<p class="endmatter-idx1">Antibiotics</p>
			<p class="endmatter-idx2">chalazion treated with, 182</p>
			<p class="endmatter-idx2">dacryocystitis treated with, 314–315</p>
			<p class="endmatter-idx2">necrotizing fasciitis treated with, 49<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">preseptal cellulitis treated with, 44–45</p>
			<p class="endmatter-idx1">Antifungal therapy, for zygomycosis, 52</p>
			<p class="endmatter-idx1">Antineutrophil cytoplasmic autoantibody (ANCA) serum assay, 34, 63</p>
			<p class="endmatter-idx1">Antoni A pattern/Antoni B pattern, 86</p>
			<p class="endmatter-idx1">AOX.&#160;<span class="endmatter-idx1_italic">See</span> Adult-&#173;onset xanthogranuloma</p>
			<p class="endmatter-idx1">Apert syndrome, 39, 39<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Apocrine hidrocystoma, 193, 193<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Aponeurotic ptosis, 245, 245<span class="endmatter-idx1_italic">t</span>, 245<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Arcus marginalis, 11</p>
			<p class="endmatter-idx1">Argon &#173;laser, for trichiasis, 240</p>
			<p class="endmatter-idx1">Arteriography, 32</p>
			<p class="endmatter-idx1">Arteriovenous fistulas, 78, 78<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Arteriovenous malformations (AVMs), 77<span class="endmatter-idx1_italic">f</span>, <br />77–78</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Aspergillus</span> (aspergillosis), 52</p>
			<p class="endmatter-idx1">Autogenous tensor fascia lata, 252</p>
			<p class="endmatter-idx1">Autoimmune hyperthyroidism, 57</p>
			<p class="endmatter-idx1">Autologous fat grafting, 271</p>
			<p class="endmatter-idx1">Autosomal dominant polyposis of the intestinal <br />tract, 197</p>
			<p class="endmatter-idx1">AVMs. <span class="endmatter-idx1_italic">See</span> Arteriovenous malformations</p>
			<p class="endmatter-idx1">Axial plane, 27</p>
			<p class="endmatter-idx1">Azithromycin, for chalazion, 182</p>
			<p class="endmatter-idx-alpha">B-&#173;cell lymphomas</p>
			<p class="endmatter-idx2">diffuse large, 92</p>
			<p class="endmatter-idx2">extranodal marginal zone, 92, 95</p>
			<p class="endmatter-idx1">B-&#173;scan ultrasonography, 31</p>
			<p class="endmatter-idx1">Balloon dacryoplasty, 294</p>
			<p class="endmatter-idx1">Basal cell carcinoma, 200–205, 201–203<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Basal cell nevus syndrome, 201</p>
			<p class="endmatter-idx1">Basal tear secretion, 296</p>
			<p class="endmatter-idx1">Battlefield injuries, 122</p>
			<p class="endmatter-idx1">BEB.&#160;<span class="endmatter-idx1_italic">See</span> Benign essential blepharospasm</p>
			<p class="endmatter-idx1">Bell phenomenon, 243</p>
			<p class="endmatter-idx1">Benign epithelial lesions, 189–190, 189–190<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Benign essential blepharospasm (BEB), <br />256–258</p>
			<p class="endmatter-idx1">Benign melanocytic lesions</p>
			<p class="endmatter-idx2">blue nevi, 198</p>
			<p class="endmatter-idx2">dermal melanocytosis, 198, 198<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">ephelis, 197</p>
			<p class="endmatter-idx2">lentigo simplex, 197</p>
			<p class="endmatter-idx2">nevi, 195–197, 196–197<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">solar lentigo, 197–198, 198<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">sources of, 194–195</p>
			<p class="endmatter-idx1">Benign mixed tumor, 99</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_symbol">β</span>-&#173;Blockers, for infantile hemangiomas, 72</p>
			<p class="endmatter-idx1">Bicanalicular lacrimal stent, 293, 294<span class="endmatter-idx1_italic">f</span>, <br />301<span class="endmatter-idx1_italic">f</span>, 312</p>
			<p class="endmatter-idx1">Bilateral hilar adenopathy, 65<span class="endmatter-idx1_italic">f</span>, 66</p>
			<p class="endmatter-idx1">Biointegrated materials, 139</p>
			<p class="endmatter-idx1">Biopsy</p>
			<p class="endmatter-idx2">excisional, 203<span class="endmatter-idx2_italic">f</span>, 204</p>
			<p class="endmatter-idx2">eyelid, 203<span class="endmatter-idx2_italic">f</span>, 203–204</p>
			<p class="endmatter-idx2">fine-&#173;needle aspiration, 132, 132<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">incisional, 203, 203<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">sentinel lymph node</p>
			<p class="endmatter-idx3">for melanoma, 210</p>
			<p class="endmatter-idx3">for sebaceous carcinoma, 208</p>
			<p class="endmatter-idx1">Bites, 218</p>
			<p class="endmatter-idx1">Blepharochalasis, 259</p>
			<p class="endmatter-idx1">Blepharophimosis–&#173;ptosis–&#173;epicanthus inversus <br />syndrome (BPES), 173–174, 174–175<span class="endmatter-idx1_italic">f</span>, 243</p>
			<p class="endmatter-idx1">Blepharoplasty</p>
			<p class="endmatter-idx2">complications of, 262–263</p>
			<p class="endmatter-idx2">diplopia &#173;after, 262–263</p>
			<p class="endmatter-idx2">lower eyelid</p>
			<p class="endmatter-idx3">description of, 260</p>
			<p class="endmatter-idx3">infraciliary incision for, 262</p>
			<p class="endmatter-idx3">&#173;laser skin resurfacing with, 268</p>
			<p class="endmatter-idx3">midface rejuvenation with, 271–272, 272<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">orbital fat redraping with, 272<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">technique for, 261–262, 262<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">transconjunctival incision for, 261, 262<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">vision loss secondary to, 262</p>
			<p class="endmatter-idx2">techniques for, 261–262, 261–262<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">upper eyelid</p>
			<p class="endmatter-idx3">brow ptosis and, 264</p>
			<p class="endmatter-idx3">description of, 259</p>
			<p class="endmatter-idx3">preoperative evaluation, 260</p>
			<p class="endmatter-idx3">retraction caused by, 253<span class="endmatter-idx3_italic">f</span>, 254</p>
			<p class="endmatter-idx1">Blepharoptosis. <span class="endmatter-idx1_italic">See</span> Ptosis</p>
			<p class="endmatter-idx1">Blepharospasm, benign essential, 256–258</p>
			<p class="endmatter-idx1">Blindness. <span class="endmatter-idx1_italic">See</span> Vision loss</p>
			<p class="endmatter-idx1">Blinking, 283</p>
			<p class="endmatter-idx1">Block-&#173;and-&#173;replace therapy, 60</p>
			<p class="endmatter-idx1">Blowout fractures, orbital</p>
			<p class="endmatter-idx2">complications of, 117</p>
			<p class="endmatter-idx2">delayed treatment of, 117</p>
			<p class="endmatter-idx2">description of, 20</p>
			<p class="endmatter-idx2">diagnosis of, 114–115</p>
			<p class="endmatter-idx2">hydraulic mechanism theory of, 114</p>
			<p class="endmatter-idx2">indirect, 113</p>
			<p class="endmatter-idx2">orbital cellulitis &#173;after, 48</p>
			<p class="endmatter-idx2">physical examination of, 114–115</p>
			<p class="endmatter-idx2">surgical management of, 117</p>
			<p class="endmatter-idx2">white-&#173;eyed, 114</p>
			<p class="endmatter-idx1">Blue nevi, 198</p>
			<p class="endmatter-idx1">Blunt trauma, of eyelid, 213</p>
			<p class="endmatter-idx1">Botryoid rhabdomyosarcomas, 88</p>
			<p class="endmatter-idx1">Botulinum toxin</p>
			<p class="endmatter-idx2">benign essential blepharospasm treated with, 256–257, 257<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">facial rejuvenation uses of, 269–270</p>
			<p class="endmatter-idx2">hemifacial spasm treated with, 258</p>
			<p class="endmatter-idx1">Bowen disease, 199–200</p>
			<p class="endmatter-idx1">BPES. <span class="endmatter-idx1_italic">See</span> Blepharophimosis–&#173;ptosis–&#173;epicanthus <br />inversus syndrome</p>
			<p class="endmatter-idx1">Breast carcinoma, metastatic, 106, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Bronchogenic carcinoma, 106</p>
			<p class="endmatter-idx1">Brow-&#173; and forehead-&#173;lift, 264–265<span class="endmatter-idx1_italic">f</span>, 265–266</p>
			<p class="endmatter-idx1">Brow ptosis</p>
			<p class="endmatter-idx2">brow-&#173; and forehead-&#173;lift for, 264–265<span class="endmatter-idx2_italic">f</span>, 265–266</p>
			<p class="endmatter-idx2">browpexy for, 264–265</p>
			<p class="endmatter-idx2">definition of, 263</p>
			<p class="endmatter-idx2">dermatochalasis and, 259, 263</p>
			<p class="endmatter-idx2">direct brow elevation for, 265</p>
			<p class="endmatter-idx2">illustration of, 263<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">management of, 263–266, 264–265<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Browpexy, 264–265</p>
			<p class="endmatter-idx1">Burns, eyelid, 218–219, 218–219<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">c-&#173;ANCA. <span class="endmatter-idx-alpha_italic">See</span> Cytoplasm-&#173;antineutrophil cytoplasmic autoantibody</p>
			<p class="endmatter-idx1">CA-&#173;MRSA. <span class="endmatter-idx1_italic">See</span> Community-&#173;acquired methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus</span></p>
			<p class="endmatter-idx1">Canaliculi, lacrimal</p>
			<p class="endmatter-idx2">accessory, 286<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">agenesis of, 288</p>
			<p class="endmatter-idx2">description of, 281</p>
			<p class="endmatter-idx2">duplication of, 286, 286<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dysgenesis of, 288</p>
			<p class="endmatter-idx2">obstruction of</p>
			<p class="endmatter-idx3">canaliculodacryocystorhinostomy for, 303</p>
			<p class="endmatter-idx3">conjunctivodacryocystorhinostomy for, 304<span class="endmatter-idx3_italic">f</span>, 304–305</p>
			<p class="endmatter-idx3">etiology of, 302–303</p>
			<p class="endmatter-idx3">evaluation of, 302</p>
			<p class="endmatter-idx3">illustration of, 299<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">infections that cause, 303</p>
			<p class="endmatter-idx3">inflammatory disease as cause of, 303</p>
			<p class="endmatter-idx3">lacrimal plugs as cause of, 302</p>
			<p class="endmatter-idx3">management of, 303–305, 304<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">medi&#173;cations that cause, 302</p>
			<p class="endmatter-idx3">neoplasm as cause of, 303</p>
			<p class="endmatter-idx3">partial, 302</p>
			<p class="endmatter-idx3">reconstruction of, 303</p>
			<p class="endmatter-idx3">stents for, 292–294, 294<span class="endmatter-idx3_italic">f</span>, 303</p>
			<p class="endmatter-idx3">total, 298, 299<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">traumatic &#173;causes of, 303</p>
			<p class="endmatter-idx2">occlusion of, 298</p>
			<p class="endmatter-idx2">probing of, 291<span class="endmatter-idx2_italic">f</span>, 291–292, 302</p>
			<p class="endmatter-idx2">stenosis of, 298</p>
			<p class="endmatter-idx2">traumatic injuries to, 311–312</p>
			<p class="endmatter-idx1">Canaliculitis, 311, 313, 314<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Canaliculodacryocystorhinostomy, 303</p>
			<p class="endmatter-idx1">Canthal tendons. <span class="endmatter-idx1_italic">See also</span> Lateral canthal tendon; <br />Medial canthal tendon</p>
			<p class="endmatter-idx2">anatomy of, 168–169, 169<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">trauma to, 214–215</p>
			<p class="endmatter-idx1">Cantholysis, 119, 124<span class="endmatter-idx1_italic">f</span>, 127<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx2">inferior, 117, 119, 120<span class="endmatter-idx1_italic">f</span>, 126, 130</p>
			<p class="endmatter-idx2">lateral, 180</p>
			<p class="endmatter-idx2">superior, 119, 222<span class="endmatter-idx1_italic">f</span>, 223<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Canthotomy, 120<span class="endmatter-idx1_italic">f</span>, 127<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx2">lateral, 117, 119, 124<span class="endmatter-idx1_italic">f</span>, 126, 129, 130, 222<span class="endmatter-idx1_italic">f</span>, 223<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Capillary hemangioma, 71<span class="endmatter-idx1_italic">f</span>, 71–73, 180–181</p>
			<p class="endmatter-idx1">Capsulopalpebral fascia, 167</p>
			<p class="endmatter-idx1">Capsulopalpebral–&#173;orbital septum complex, 163</p>
			<p class="endmatter-idx1">Carbon dioxide (CO<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>) &#173;lasers, 268</p>
			<p class="endmatter-idx1">Carcinoma. <span class="endmatter-idx1_italic">See also</span> <span class="italic">specific type</span></p>
			<p class="endmatter-idx2">adenoid cystic, 100</p>
			<p class="endmatter-idx2">basal cell, 200–205, 201<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">bronchogenic, 106</p>
			<p class="endmatter-idx2">Merkel cell, 212, 212<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">metastatic breast, 106, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">prostate, 107</p>
			<p class="endmatter-idx2">sebaceous, 206 207<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">squamous cell, 102, 103<span class="endmatter-idx1_italic">f</span>, 199, 205–206, 206<span class="endmatter-idx2_italic">f</span>, 316<span class="endmatter-idx2_italic">f</span>, 317</p>
			<p class="endmatter-idx1">Carotid-&#173;cavernous fistulas</p>
			<p class="endmatter-idx2">description of, 25</p>
			<p class="endmatter-idx2">direct, 78, 78<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">indirect, 79</p>
			<p class="endmatter-idx1">CAS.&#160;<span class="endmatter-idx1_italic">See</span> Clinical Activity Score</p>
			<p class="endmatter-idx1">Cavernous hemangiomas, 75</p>
			<p class="endmatter-idx1">Cavernous sinus thrombosis, 48, 51</p>
			<p class="endmatter-idx1">Cavernous venous malformations (CVMs), 75–77, 76<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">CD40 receptors, 57</p>
			<p class="endmatter-idx1">CD154, 57</p>
			<p class="endmatter-idx1">CDCR. <span class="endmatter-idx1_italic">See</span> Conjunctivodacryocystorhinostomy</p>
			<p class="endmatter-idx1">Cell-&#173;marker studies, 33–34</p>
			<p class="endmatter-idx1">Cellulitis</p>
			<p class="endmatter-idx2">orbital, 46<span class="endmatter-idx2_italic">t</span>, 46–48, 47<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">preseptal, 43–46, 44<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx1">Central fat compartment, 261</p>
			<p class="endmatter-idx1">Central ret&#173;i&#173;nal artery occlusion, 271</p>
			<p class="endmatter-idx1">Central surgical space, 12</p>
			<p class="endmatter-idx1">Cervicoplasty, 276<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Chalazion, 181–183, 182–183<span class="endmatter-idx1_italic">f</span>, 191, 207, 248, 248<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Checkpoint inhibitors, 206, 210–211</p>
			<p class="endmatter-idx1">Chemotherapy</p>
			<p class="endmatter-idx2">optic nerve glioma treated with, 82–83</p>
			<p class="endmatter-idx2">rhabdomyosarcomas treated with, 88–89</p>
			<p class="endmatter-idx1">&#173;Children</p>
			<p class="endmatter-idx2">computed tomography in, 31</p>
			<p class="endmatter-idx2">enucleation in, 137</p>
			<p class="endmatter-idx2">metastatic neuroblastoma in, 22<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">metastatic tumors in, 104–105</p>
			<p class="endmatter-idx2">orbital floor fractures in, 115, 116<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">rhabdomyosarcoma in, 87</p>
			<p class="endmatter-idx1">Chloasma, 195</p>
			<p class="endmatter-idx1">Choco&#173;late cysts, 74</p>
			<p class="endmatter-idx1">Chondroid syringoma, 192</p>
			<p class="endmatter-idx1">Chondrosarcoma, 91</p>
			<p class="endmatter-idx1">Choristomas, 40</p>
			<p class="endmatter-idx1">Choroidal melanoma, 136</p>
			<p class="endmatter-idx1">Chronic dacryocystitis, 315</p>
			<p class="endmatter-idx1">Chronic necrotizing aspergillosis, 52</p>
			<p class="endmatter-idx1">Chronic papillary conjunctivitis, 185</p>
			<p class="endmatter-idx1">Cicatricial ectropion</p>
			<p class="endmatter-idx2">clinical features of, 230<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">surgical repair of, 233<span class="endmatter-idx2_italic">f</span>, 233–234</p>
			<p class="endmatter-idx1">Cicatricial entropion, 237–238<span class="endmatter-idx1_italic">f</span>, 237–239</p>
			<p class="endmatter-idx1">Cicatrization, 219</p>
			<p class="endmatter-idx1">Cilia. <span class="endmatter-idx1_italic">See</span> Eyelashes</p>
			<p class="endmatter-idx1">Ciliary margin, 170</p>
			<p class="endmatter-idx1">Clindamycin, for necrotizing fasciitis, 49</p>
			<p class="endmatter-idx1">Clinical Activity Score (CAS), 58, 59<span class="endmatter-idx1_italic">t</span></p>
			<p class="endmatter-idx1">CO<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span> &#173;lasers. <span class="endmatter-idx1_italic">See</span> Carbon dioxide (CO<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>) &#173;lasers</p>
			<p class="endmatter-idx1">Coloboma, congenital, 179–180, 180<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Combined lymphatic venous malformations, 74</p>
			<p class="endmatter-idx1">Community-&#173;acquired methicillin-&#173;resistant <br /><span class="endmatter-idx1_italic">Staphylococcus aureus</span> (CA-MRSA), 45</p>
			<p class="endmatter-idx1">Compound nevus, 196, 196<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Compressive optic neuropathy, 60–61</p>
			<p class="endmatter-idx1">Computed tomography (CT)</p>
			<p class="endmatter-idx2">cavernous venous malformations on, 76<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">in &#173;children, 31</p>
			<p class="endmatter-idx2">dacryocystocele on, 290<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dermoid cysts on, 41</p>
			<p class="endmatter-idx2">fibrous dysplasia on, 89, 90<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">immunoglobulin G4–&#173;related disease on, 66<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">indications for, 300</p>
			<p class="endmatter-idx2">Langerhans cell histiocytosis on, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">lymphoproliferative disorders on, 93<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">magnetic resonance imaging versus, 29<span class="endmatter-idx2_italic">t</span>, 29–31</p>
			<p class="endmatter-idx2">necrotizing fasciitis on, 49<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">nonspecific orbital inflammation on, 68<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">optic nerve glioma on, 80–81</p>
			<p class="endmatter-idx2">orbital compartment syndrome on, 118<span class="endmatter-idx2_italic">f</span>, 120<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital disorders evaluated using, 26<span class="endmatter-idx2_italic">f</span>, 26–27</p>
			<p class="endmatter-idx2">orbital floor fractures on, 116</p>
			<p class="endmatter-idx2">orbital foreign bodies on, 117–118, 118<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">sarcoidosis on, 65<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">&#173;silent sinus syndrome on, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">solitary fibrous tumor on, 89</p>
			<p class="endmatter-idx2">sphenoid wing meningioma on, 84<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">zygomycosis on, 51<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Computed tomography (CT) angiography</p>
			<p class="endmatter-idx2">arteriovenous malformations on, 77<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">description of, 32</p>
			<p class="endmatter-idx1">Congenital disorders</p>
			<p class="endmatter-idx2">anophthalmia. <span class="endmatter-idx2_italic">See</span> Anophthalmia</p>
			<p class="endmatter-idx2">craniofacial clefts, 38–39</p>
			<p class="endmatter-idx2">distichiasis, 170, 179, 179<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">ectropion, 174, 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">entropion, 179, 179<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">of eyelids. <span class="endmatter-idx2_italic">See</span> Eyelid disorders, congenital</p>
			<p class="endmatter-idx2">Horner syndrome, 246</p>
			<p class="endmatter-idx2">microphthalmia, 36–38</p>
			<p class="endmatter-idx2">myogenic ptosis, 244, 244<span class="endmatter-idx2_italic">f</span>, 245<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">nasolacrimal duct obstruction. <span class="endmatter-idx2_italic">See</span> Nasolacrimal duct obstruction, congenital</p>
			<p class="endmatter-idx2">oculomotor nerve palsy, 246</p>
			<p class="endmatter-idx2">orbital tumors. <span class="endmatter-idx2_italic">See</span> Orbital tumors, congenital</p>
			<p class="endmatter-idx2">overview of, 35</p>
			<p class="endmatter-idx2">syndromic craniosynostosis, 39, 39<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">tumors, 40–42</p>
			<p class="endmatter-idx1">Conjunctiva</p>
			<p class="endmatter-idx2">anatomy of, 168</p>
			<p class="endmatter-idx2">cyst of, 141, 141<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">epithelium of, 296</p>
			<p class="endmatter-idx1">Conjunctivitis</p>
			<p class="endmatter-idx2">chronic papillary, 185</p>
			<p class="endmatter-idx2">follicular, 190, 190<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">&#173;giant papillary, 142, 142<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Conjunctivochalasis, 297<span class="endmatter-idx1_italic">f</span>, 302</p>
			<p class="endmatter-idx1">Conjunctivodacryocystorhinostomy (CDCR), 288, 304<span class="endmatter-idx1_italic">f</span>, 304–305, 307, 311</p>
			<p class="endmatter-idx1">Consecutive anophthalmia, 35</p>
			<p class="endmatter-idx1">Contracted fornices, 143</p>
			<p class="endmatter-idx1">Contracted sockets, 143–144, 144<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Contrast dacryocystography, 300</p>
			<p class="endmatter-idx1">Corneal abrasion, 214</p>
			<p class="endmatter-idx1">Corneal epithelium, 296</p>
			<p class="endmatter-idx1">Corneal irritation, 296</p>
			<p class="endmatter-idx1">Coronal plane, 27</p>
			<p class="endmatter-idx1">Corrugator supercilii muscle, 153, 154<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Corticosteroids</p>
			<p class="endmatter-idx2">chalazion treated with, 183</p>
			<p class="endmatter-idx2">immunoglobulin G4–&#173;related disease treated with, 67</p>
			<p class="endmatter-idx2">infantile (capillary) hemangioma treated with, 181</p>
			<p class="endmatter-idx2">infantile hemangiomas treated with, 72</p>
			<p class="endmatter-idx2">nonspecific orbital inflammation treated with, 69–70</p>
			<p class="endmatter-idx2">orbital cellulitis treated with, 48</p>
			<p class="endmatter-idx1">Cosmetic blepharoplasty, 253<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Craniofacial anomalies, syndromic, 38–39</p>
			<p class="endmatter-idx1">Craniofacial clefts, 38–39</p>
			<p class="endmatter-idx1">Craniosynostosis, syndromic, 39, 39<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Crawford stent and hook, 293, 293<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Crouzon syndrome, 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Cryotherapy, 205, 210, 240</p>
			<p class="endmatter-idx1">Cryptophthalmos, 180, 181<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">CT.&#160;<span class="endmatter-idx1_italic">See</span> Computed tomography</p>
			<p class="endmatter-idx1">CT angiography. <span class="endmatter-idx1_italic">See</span> Computed tomography (CT) angiography</p>
			<p class="endmatter-idx1">Cutaneous horn, 188–189</p>
			<p class="endmatter-idx1">Cutler-&#173;Beard flap, 221, 223<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">CVMs.&#160;<span class="endmatter-idx1_italic">See</span> Cavernous venous malformations</p>
			<p class="endmatter-idx1">Cylindroma, 193, 193<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Cysticercosis, 53</p>
			<p class="endmatter-idx1">Cytokines, 210</p>
			<p class="endmatter-idx1">Cytoplasm-&#173;antineutrophil cytoplasmic autoantibody (c-&#173;ANCA), 63</p>
			<p class="endmatter-idx-alpha">Dacryoadenitis, 68, 98, 312–313</p>
			<p class="endmatter-idx1">Dacryocystectomy, 317</p>
			<p class="endmatter-idx1">Dacryocystitis, 289, 313–315, 315<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Dacryocystocele, 289, 290<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Dacryocystography, 300</p>
			<p class="endmatter-idx1">Dacryocystorhinostomy (DCR)</p>
			<p class="endmatter-idx2">dacryocystitis treated with, 315</p>
			<p class="endmatter-idx2">nasolacrimal duct obstruction treated with, 286, 295, 307–310, 308–309<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Dacryolith, 305<span class="endmatter-idx1_italic">f</span>, 305–306, 313</p>
			<p class="endmatter-idx1">Dacryoscintigraphy, 300</p>
			<p class="endmatter-idx1">DCR.&#160;<span class="endmatter-idx1_italic">See</span> Dacryocystorhinostomy</p>
			<p class="endmatter-idx1">DDT.&#160;<span class="endmatter-idx1_italic">See</span> Dye disappearance test</p>
			<p class="endmatter-idx1">Deep cervical fascia, 153</p>
			<p class="endmatter-idx1">Deep mimetic muscles, 153</p>
			<p class="endmatter-idx1">Deep superior sulcus, 141, 141<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Deep temporal fascia, 155</p>
			<p class="endmatter-idx1">Dermal fillers, for facial rejuvenation, 270<span class="endmatter-idx1_italic">f</span>, 270–271</p>
			<p class="endmatter-idx1">Dermal melanocytosis, 198, 198<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Dermal nevus, 196</p>
			<p class="endmatter-idx1">Dermatochalasis</p>
			<p class="endmatter-idx2">brow ptosis and, 259, 263</p>
			<p class="endmatter-idx2">description of, 249, 249<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Dermis-&#173;fat grafts, 36, 37<span class="endmatter-idx1_italic">f</span>, 137, 141, 143, 143<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Dermoid cyst, 40–41</p>
			<p class="endmatter-idx1">Dermolipoma, 41, 42<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Diffuse large B-&#173;cell lymphomas (DLBCL), 92</p>
			<p class="endmatter-idx1">Digital eversion, for cicatricial entropion, 237</p>
			<p class="endmatter-idx1">Diplopia</p>
			<p class="endmatter-idx2">&#173;after blepharoplasty, 262–263</p>
			<p class="endmatter-idx2">in orbital blowout fractures, 114</p>
			<p class="endmatter-idx2">in orbital floor fractures, 115–116</p>
			<p class="endmatter-idx2">thyroid eye disease and, 61–62</p>
			<p class="endmatter-idx1">Direct carotid-&#173;cavernous fistulas, 78, 78<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Direct coronal scans, 27</p>
			<p class="endmatter-idx1">Direct traumatic optic neuropathy, 121<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Discrete neurofibromas, 83</p>
			<p class="endmatter-idx1">Distensible venous malformations, 74–75, 75<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Distichiasis, 170, 179, 179<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Distraction test, for horizontal eyelid laxity, 231</p>
			<p class="endmatter-idx1">DLBCL. <span class="endmatter-idx1_italic">See</span> Diffuse large B-&#173;cell lymphomas</p>
			<p class="endmatter-idx1">Dog bites, 218</p>
			<p class="endmatter-idx1">Doppler ultrasonography, 31</p>
			<p class="endmatter-idx1">Double-&#173;elevator palsy, 245</p>
			<p class="endmatter-idx1">Double freeze–&#173;thaw technique, 240</p>
			<p class="endmatter-idx1">Dry eye disease, 310</p>
			<p class="endmatter-idx1">Duane retraction syndrome, 243</p>
			<p class="endmatter-idx1">Dural tail, 85</p>
			<p class="endmatter-idx1">Dye disappearance test (DDT), 297, 298<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Ecchymosis, eyelid, 22, 22<span class="endmatter-idx-alpha_italic">f</span>, 23<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="endmatter-idx1">Eccrine hidrocystoma, 191</p>
			<p class="endmatter-idx1">Eccrine spiradenomas, 193</p>
			<p class="endmatter-idx1">Eccrine sweat glands</p>
			<p class="endmatter-idx2">anatomy of, 191</p>
			<p class="endmatter-idx2">tumors of, 191–192</p>
			<p class="endmatter-idx1">ECD. <span class="endmatter-idx1_italic">See</span> Erdheim-Chester disease</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Echinococcus granulosus</span> (echinococcus), 53</p>
			<p class="endmatter-idx1">Ectropion</p>
			<p class="endmatter-idx2">anophthalmic, 144, 144<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">cicatricial</p>
			<p class="endmatter-idx3">clinical features of, 230<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">surgical repair of, 233<span class="endmatter-idx3_italic">f</span>, 233–234</p>
			<p class="endmatter-idx2">classification of, 229, 231</p>
			<p class="endmatter-idx2">congenital, 174, 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">definition of, 229</p>
			<p class="endmatter-idx2">involutional</p>
			<p class="endmatter-idx3">clinical features of, 230<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">horizontal eyelid laxity as cause of, 231</p>
			<p class="endmatter-idx3">lateral tarsal strip procedure for, 231, 232<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">lower eyelid tightening surgery for, 231, 232<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">medial spindle procedure for, 231, 232<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">mechanical, 230<span class="endmatter-idx2_italic">f</span>, 234</p>
			<p class="endmatter-idx2">paralytic, 230<span class="endmatter-idx2_italic">f</span>, 254–255</p>
			<p class="endmatter-idx2">tarsal, 232</p>
			<p class="endmatter-idx2">types of, 229–231, 230<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Electrolysis, for trichiasis, 240</p>
			<p class="endmatter-idx1">Embryonal rhabdomyosarcomas, 88</p>
			<p class="endmatter-idx1">Emphysema, orbital, 115</p>
			<p class="endmatter-idx1">EMZL. <span class="endmatter-idx1_italic">See</span> Extranodal marginal zone B-&#173;cell lymphoma</p>
			<p class="endmatter-idx1">Encephalocele, 39</p>
			<p class="endmatter-idx1">Endonasal dacryocystorhinostomy, 307, 309, 309<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Endophthalmitis, 138</p>
			<p class="endmatter-idx1">Endoscopic brow-&#173; and forehead-&#173;lift, 264<span class="endmatter-idx1_italic">f</span>, 265</p>
			<p class="endmatter-idx1">Endoscopic dacryocystorhinostomy, 309</p>
			<p class="endmatter-idx1">Endoscopic transnasal surgery, 132</p>
			<p class="endmatter-idx1">Endovascular coiling, for carotid-&#173;cavernous fistula, 79<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Enophthalmos, 24</p>
			<p class="endmatter-idx2">definition of, 23</p>
			<p class="endmatter-idx2">in metastatic breast carcinoma, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">in orbital blowout fractures, 114–115</p>
			<p class="endmatter-idx2">in orbital floor fractures, 116</p>
			<p class="endmatter-idx1">Entropion</p>
			<p class="endmatter-idx2">acute spastic, 237</p>
			<p class="endmatter-idx2">cicatricial, 237–238<span class="endmatter-idx2_italic">f</span>, 237–239</p>
			<p class="endmatter-idx2">congenital, 179, 179<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">involutional</p>
			<p class="endmatter-idx3">&#173;causes of, 234</p>
			<p class="endmatter-idx3">clinical features of, 235<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">retractor disinsertion as cause of, 234–235</p>
			<p class="endmatter-idx3">surgical repair of, 236, 236<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">temporizing mea&#173;sures for, 235<span class="endmatter-idx3_italic">f</span>, 235–236</p>
			<p class="endmatter-idx3">transconjunctival approach to, 236, 236<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">lower eyelid, 234</p>
			<p class="endmatter-idx2">marginal, 238</p>
			<p class="endmatter-idx2">spastic, 235<span class="endmatter-idx2_italic">f</span>, 237</p>
			<p class="endmatter-idx2">upper eyelid, 234</p>
			<p class="endmatter-idx1">Enucleation</p>
			<p class="endmatter-idx2">in &#173;children, 137</p>
			<p class="endmatter-idx2">complications of, 138–139</p>
			<p class="endmatter-idx2">conjunctival cyst &#173;after, 141<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">definition of, 135</p>
			<p class="endmatter-idx2">description of, 36</p>
			<p class="endmatter-idx2">indications for, 136</p>
			<p class="endmatter-idx2">prostheses &#173;after, 140–141, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">removal of wrong eye, 138</p>
			<p class="endmatter-idx1">Ephelis, 197</p>
			<p class="endmatter-idx1">Epiblepharon, 176<span class="endmatter-idx1_italic">f</span>, 178–179</p>
			<p class="endmatter-idx1">Epicanthus, 176–177, 176–177<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx2">inversus, 177</p>
			<p class="endmatter-idx2">palpebralis, 177</p>
			<p class="endmatter-idx2">supraciliaris, 177</p>
			<p class="endmatter-idx2">tarsalis, 177–178<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Epidermal inclusion cysts, 189, 189<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Epidermoid cysts, 40</p>
			<p class="endmatter-idx1">Epimyoepithelial islands, 101</p>
			<p class="endmatter-idx1">Epiphora, 292, 296, 301, 301<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Epithelial hyperplasia, 187–189, 188<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Epstein-&#173;Barr virus, 313</p>
			<p class="endmatter-idx1">Erbium:yttrium-&#173;aluminum-&#173;garnet (Er:YAG) &#173;lasers, 268</p>
			<p class="endmatter-idx1">Erdheim-&#173;Chester disease (ECD), 97, 98<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Er:YAG &#173;lasers. <span class="endmatter-idx1_italic">See</span> Erbium:yttrium-&#173;aluminum-&#173;garnet (Er:YAG) &#173;lasers</p>
			<p class="endmatter-idx1">Ethmoid air cells, 19–20, 282</p>
			<p class="endmatter-idx1">Ethmoid bone, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Ethmoid sinus</p>
			<p class="endmatter-idx2">air cells of, 20</p>
			<p class="endmatter-idx2">bacterial infections of, 8</p>
			<p class="endmatter-idx2">squamous cell carcinoma of, 102, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Ethmoidal foramen, 9</p>
			<p class="endmatter-idx1">Euryblepharon, 174–175, 176–177<span class="endmatter-idx1_italic">f</span>, 178<span class="endmatter-idx1_italic">f</span>, 178–179</p>
			<p class="endmatter-idx1">Evisceration</p>
			<p class="endmatter-idx2">advantages of, 138</p>
			<p class="endmatter-idx2">complications of, 138–139</p>
			<p class="endmatter-idx2">definition of, 135, 137</p>
			<p class="endmatter-idx2">disadvantages of, 138</p>
			<p class="endmatter-idx2">prostheses &#173;after, 140–141, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Excisional biopsy, 203<span class="endmatter-idx1_italic">f</span>, 204</p>
			<p class="endmatter-idx1">Exenteration</p>
			<p class="endmatter-idx2">basal cell carcinoma treated with, 204</p>
			<p class="endmatter-idx2">considerations for, 146</p>
			<p class="endmatter-idx2">definition of, 135</p>
			<p class="endmatter-idx2">extended, 146</p>
			<p class="endmatter-idx2">lacrimal drainage system tumors treated with, 317</p>
			<p class="endmatter-idx2">rhabdomyosarcomas treated with, 89</p>
			<p class="endmatter-idx2">sebaceous carcinoma treated with, 207</p>
			<p class="endmatter-idx2">subtotal, 146</p>
			<p class="endmatter-idx2">total, 146, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">types of, 146–147, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Exophthalmometers, 24, 24<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Exophthalmometry, 24, 24<span class="endmatter-idx1_italic">f</span>, 116</p>
			<p class="endmatter-idx1">Exophthalmos, 23, 112</p>
			<p class="endmatter-idx1">Exorbitism, 23</p>
			<p class="endmatter-idx1">Exposure keratopathy, 254</p>
			<p class="endmatter-idx1">Extended exenteration, 146</p>
			<p class="endmatter-idx1">External carotid artery, 170</p>
			<p class="endmatter-idx1">External dacryocystorhinostomy, 307, 308<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">External hordeolum, 183</p>
			<p class="endmatter-idx1">Extraconal fat, 12</p>
			<p class="endmatter-idx1">Extracoronal surgical space, 123<span class="endmatter-idx1_italic">f</span>, 123–124</p>
			<p class="endmatter-idx1">Extranodal marginal zone B-&#173;cell lymphoma (EMZL), 92, 95</p>
			<p class="endmatter-idx1">Extraocular muscles</p>
			<p class="endmatter-idx2">anatomy of, 12, 12<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">assessment of, 243</p>
			<p class="endmatter-idx2">damage to, 139</p>
			<p class="endmatter-idx2">function of, 11–12, 243</p>
			<p class="endmatter-idx2">innervation of, 12–13</p>
			<p class="endmatter-idx2">orbital implant migration caused by displacement of, 140<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Exuberant hyperkeratosis, 188</p>
			<p class="endmatter-idx1">Eyebrows</p>
			<p class="endmatter-idx2">botulinum toxin injection in, 269</p>
			<p class="endmatter-idx2">ptosis. <span class="endmatter-idx2_italic">See</span> Brow ptosis</p>
			<p class="endmatter-idx1">Eyelashes, 170, 171. <span class="endmatter-idx1_italic">See also</span> Distichiasis; Epiblepharon; Trichiasis; Trichotillomania</p>
			<p class="endmatter-idx1">Eyelid(s). <span class="endmatter-idx1_italic">See also</span> Lower eyelids; Upper eyelids</p>
			<p class="endmatter-idx2">arterial supply of, 170</p>
			<p class="endmatter-idx2">biopsy of, 203<span class="endmatter-idx2_italic">f</span>, 203–204</p>
			<p class="endmatter-idx2">blepharoptosis of. <span class="endmatter-idx2_italic">See</span> Ptosis</p>
			<p class="endmatter-idx2">canthal tendons of, 168–169, 169<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">connective tissue of, 168–169</p>
			<p class="endmatter-idx2">crease of, 160</p>
			<p class="endmatter-idx2">ecchymosis of, 22, 22<span class="endmatter-idx2_italic">f</span>, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">edema of, 84, 184, 184<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">emphysema of, 115</p>
			<p class="endmatter-idx2">eversion of, 174, 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fibrous anatomy of, 165<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fold of, 160–161</p>
			<p class="endmatter-idx2">horizontal laxity of, 231, 234</p>
			<p class="endmatter-idx2">lag in. <span class="endmatter-idx2_italic">See</span> Lid lag </p>
			<p class="endmatter-idx2">lymphatic supply of, 170–171</p>
			<p class="endmatter-idx2">lymphedema of, 184, 184<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">malpositions of</p>
			<p class="endmatter-idx3">blepharoptosis. <span class="endmatter-idx3_italic">See</span> Ptosis</p>
			<p class="endmatter-idx3">ectropion. <span class="endmatter-idx3_italic">See</span> Ectropion</p>
			<p class="endmatter-idx3">entropion. <span class="endmatter-idx3_italic">See</span> Entropion</p>
			<p class="endmatter-idx3">history-&#173;taking for, 229</p>
			<p class="endmatter-idx3">physical examination of, 229</p>
			<p class="endmatter-idx3">symblepharon, 239</p>
			<p class="endmatter-idx3">trichiasis, 239<span class="endmatter-idx3_italic">f</span>, 239–240</p>
			<p class="endmatter-idx2">meibomian glands of, 170</p>
			<p class="endmatter-idx2">milia of, 189, 189<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">muscles of</p>
			<p class="endmatter-idx3">levator, 165, 165<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">for protraction, 161–163, 162–163<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">for retraction, 164–167, 165–167<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">neoplasms of. <span class="endmatter-idx2_italic">See</span> Eyelid neoplasms and tumors</p>
			<p class="endmatter-idx2">orbital fat, 164, 164<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital septum, 163–164</p>
			<p class="endmatter-idx2">orbital tumors from, 101</p>
			<p class="endmatter-idx2">protraction of, muscles for, 161–163, 162–163<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">ptosis of. <span class="endmatter-idx2_italic">See</span> Ptosis</p>
			<p class="endmatter-idx2">racial variations in, 160–161, 161<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">retraction of, muscles for, 164–167, 165–167<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">skin of, 159–161, 160–161<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">structural layers of, 159–171</p>
			<p class="endmatter-idx2">subcutaneous connective tissue of, 159–161</p>
			<p class="endmatter-idx2">suborbicular fat pads of, 168</p>
			<p class="endmatter-idx2">suspensory anatomy of, 165<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">tarsus of, 168, 169<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">traumatic injuries to. <span class="endmatter-idx2_italic">See</span> Eyelid trauma</p>
			<p class="endmatter-idx2">tumors of. <span class="endmatter-idx2_italic">See</span> Eyelid neoplasms and tumors</p>
			<p class="endmatter-idx2">vascular supply of, 157, 158–159<span class="endmatter-idx2_italic">f</span>, 170–171</p>
			<p class="endmatter-idx2">venous drainage of, 171</p>
			<p class="endmatter-idx1">Eyelid disorders</p>
			<p class="endmatter-idx2">chalazion, 181–183, 182–183<span class="endmatter-idx2_italic">f</span>, 191, 207</p>
			<p class="endmatter-idx2">congenital</p>
			<p class="endmatter-idx3">ankyloblepharon, 175–176, 176–177<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">blepharophimosis–&#173;ptosis–&#173;epicanthus inversus syndrome, 173–174, 174–175<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">coloboma, 179–180, 180<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">cryptophthalmos, 180, 181<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">distichiasis, 179, 179<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">ectropion, 174, 176<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">entropion, 179, 179<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">epiblepharon, 176<span class="endmatter-idx3_italic">f</span>, 178–179</p>
			<p class="endmatter-idx3">epicanthus, 176–177, 176–177<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">euryblepharon, 174–175, 176–177<span class="endmatter-idx3_italic">f</span>, 178<span class="endmatter-idx3_italic">f</span>, 178–179</p>
			<p class="endmatter-idx3">infantile (capillary) hemangioma, 180–181</p>
			<p class="endmatter-idx2">edema, 184, 184<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">eyelid imbrication syndrome, 185–186</p>
			<p class="endmatter-idx2">floppy eyelid syndrome, 184–185, 185<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">hordeolum, 183–184, 184<span class="endmatter-idx2_italic">f</span>, 191</p>
			<p class="endmatter-idx2">lymphedema, 184, 184<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">neoplasms. <span class="endmatter-idx2_italic">See</span> Eyelid neoplasms and tumors</p>
			<p class="endmatter-idx2">trichotillomania, 186, 186<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Eyelid imbrication syndrome, 185–186</p>
			<p class="endmatter-idx1">Eyelid margin</p>
			<p class="endmatter-idx2">anatomy of, 163, 163<span class="endmatter-idx2_italic">f</span>, 170, 170<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">ectropion of. <span class="endmatter-idx2_italic">See</span> Ectropion</p>
			<p class="endmatter-idx2">inspection of, 288</p>
			<p class="endmatter-idx2">inversion of, 179</p>
			<p class="endmatter-idx2">lacerations of, 214, 215–216<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">nevus of, 196<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">reconstruction for defects involving, 220–225</p>
			<p class="endmatter-idx2">sebaceous carcinoma of, 207</p>
			<p class="endmatter-idx2">upper eyelid crease to, mea&#173;sure&#173;ment of, 242</p>
			<p class="endmatter-idx1">Eyelid neoplasms and tumors</p>
			<p class="endmatter-idx2">actinic keratosis, 198–199, 199<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">adnexal lesions, 190–194, 191–192<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">apocrine hidrocystoma, 193, 193<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">benign epithelial lesions, 189–190, 189–190<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">benign melanocytic lesions</p>
			<p class="endmatter-idx3">blue nevi, 198</p>
			<p class="endmatter-idx3">dermal melanocytosis, 198, 198<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">ephelis, 197</p>
			<p class="endmatter-idx3">lentigo simplex, 197</p>
			<p class="endmatter-idx3">nevi, 195–197, 196–197<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">solar lentigo, 197–198, 198<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">sources of, 194–195</p>
			<p class="endmatter-idx2">clinical evaluation of, 186–187</p>
			<p class="endmatter-idx2">cutaneous horn, 188–189</p>
			<p class="endmatter-idx2">cylindroma, 193, 193<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">eccrine hidrocystoma, 191</p>
			<p class="endmatter-idx2">epithelial hyperplasia, 187–189, 188<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">in situ epithelial malignancies, 199–200</p>
			<p class="endmatter-idx2">keratoacanthoma, 199–200</p>
			<p class="endmatter-idx2">lentigo maligna, 200</p>
			<p class="endmatter-idx2">malignant</p>
			<p class="endmatter-idx3">basal cell carcinoma, 200–205, 201–203<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">Kaposi sarcoma, 211, 211<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">melanoma, 208–211, 209<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">Merkel cell carcinoma, 212, 212<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">sebaceous carcinoma, 206–208, 207<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">squamous cell carcinoma, 205–206, 206<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">pilomatricoma, 194, 195<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">premalignant epidermal lesions, 198–199, 199<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">premalignant melanocytic lesions, 200</p>
			<p class="endmatter-idx2">pseudoepitheliomatous hyperplasia, 188</p>
			<p class="endmatter-idx2">sebaceous adenoma, 191</p>
			<p class="endmatter-idx2">sebaceous hyperplasia, 191</p>
			<p class="endmatter-idx2">squamous cell carcinoma in situ, 199</p>
			<p class="endmatter-idx2">syringomas, 192, 192<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">trichilemmoma, 194</p>
			<p class="endmatter-idx2">trichoepithelioma, 193, 194<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">trichofolliculoma, 193, 194<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">verruca vulgaris, 188, 188<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Eyelid reconstruction</p>
			<p class="endmatter-idx2">eyelid defects</p>
			<p class="endmatter-idx3">lower eyelid, 222–225, 223–224<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">not involving eyelid margin, 220, 221<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">upper eyelid, 220–221, 222<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">for eyelid trauma. <span class="endmatter-idx2_italic">See</span> Eyelid trauma</p>
			<p class="endmatter-idx2">indications for, 205</p>
			<p class="endmatter-idx2">lateral canthal defects, 225, 226–227<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">medial canthal defects, 226, 227<span class="endmatter-idx2_italic">f</span>, 228</p>
			<p class="endmatter-idx2">princi&#173;ples of, 220</p>
			<p class="endmatter-idx2">priorities in, 219–220</p>
			<p class="endmatter-idx1">Eyelid retraction</p>
			<p class="endmatter-idx2">bilateral, 253, 254<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">&#173;causes of, 253</p>
			<p class="endmatter-idx2">congenital, 253</p>
			<p class="endmatter-idx2">definition of, 252</p>
			<p class="endmatter-idx2">iatrogenic, 253</p>
			<p class="endmatter-idx2">lower, 252, 253<span class="endmatter-idx2_italic">f</span>, 254</p>
			<p class="endmatter-idx2">management of, 253</p>
			<p class="endmatter-idx2">thyroid eye disease as cause of, 253</p>
			<p class="endmatter-idx2">upper, 253, 254<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Eyelid trauma</p>
			<p class="endmatter-idx2">blunt, 213</p>
			<p class="endmatter-idx2">burns, 218–219, 218–219<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">canthal soft tissue, 214–216</p>
			<p class="endmatter-idx2">dog bites as cause of, 218</p>
			<p class="endmatter-idx2">&#173;human bites as cause of, 218</p>
			<p class="endmatter-idx2">lacerations, 214–216<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">management of, 213</p>
			<p class="endmatter-idx2">margin, 214, 215–216<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">penetrating, 213–216</p>
			<p class="endmatter-idx2">secondary repair of, 216–218, 217<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">tarsoconjunctival flaps for, 218</p>
			<p class="endmatter-idx-alpha">Face</p>
			<p class="endmatter-idx2">aging. <span class="endmatter-idx2_italic">See</span> Aging face</p>
			<p class="endmatter-idx2">arterial network of, 157, 158–159<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">mimetic muscles of, 153, 154<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">rejuvenation techniques for. <span class="endmatter-idx2_italic">See</span> Facial rejuvenation</p>
			<p class="endmatter-idx2">sensory innervation of, 155</p>
			<p class="endmatter-idx2">superficial musculoaponeurotic system of, <br />151–153, 152<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">temporoparietal fascia of, 151, 153</p>
			<p class="endmatter-idx2">vascular supply of, 157, 158–159<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Facial dystonia</p>
			<p class="endmatter-idx2">benign essential blepharospasm, 256–258</p>
			<p class="endmatter-idx2">hemifacial spasm, 258</p>
			<p class="endmatter-idx1">Facial nerve</p>
			<p class="endmatter-idx2">anatomy of, 152<span class="endmatter-idx2_italic">f</span>, 153, 155–156<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">branches of, 156<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">muscles innervated by, 155</p>
			<p class="endmatter-idx2">nonmotor pathways of, 280<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">palsy of</p>
			<p class="endmatter-idx3">aberrant regeneration &#173;after, 258</p>
			<p class="endmatter-idx3">brow ptosis &#173;after, 263</p>
			<p class="endmatter-idx3">lacrimal pump function affected by, 296, <br />297<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">paralytic ectropion secondary to, 297<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">parasympathetic fibers of, 280</p>
			<p class="endmatter-idx2">surgical ablation of, 258</p>
			<p class="endmatter-idx2">temporal branch of, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Facial paralysis</p>
			<p class="endmatter-idx2">paralytic ectropion, 254–255</p>
			<p class="endmatter-idx2">upper eyelid paralysis, 255–256</p>
			<p class="endmatter-idx1">Facial rejuvenation</p>
			<p class="endmatter-idx2">autologous fat grafting for, 271</p>
			<p class="endmatter-idx2">botulinum toxin for, 269–270</p>
			<p class="endmatter-idx2">dermal fillers for, 270<span class="endmatter-idx2_italic">f</span>, 270–271</p>
			<p class="endmatter-idx2">hyaluronic acid fillers for, 270, 270<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">&#173;laser skin resurfacing for, 268–269</p>
			<p class="endmatter-idx2">nonsurgical, 268–271, 270<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">soft-&#173;tissue dermal fillers for, 270<span class="endmatter-idx2_italic">f</span>, 270–271</p>
			<p class="endmatter-idx2">surgical techniques for, 271–276, 272–275<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Facial surgery, 271–276, 272–275<span class="endmatter-idx1_italic">f</span>. <span class="endmatter-idx1_italic">See also specific procedure</span></p>
			<p class="endmatter-idx1">Fasanella-&#173;Servat procedure, 250</p>
			<p class="endmatter-idx1">Fascia lata, 255</p>
			<p class="endmatter-idx1">Fat. <span class="endmatter-idx1_italic">See</span> Orbital fat</p>
			<p class="endmatter-idx1">Fat decompression, 130</p>
			<p class="endmatter-idx1">Fibroblasts, orbital, 57</p>
			<p class="endmatter-idx1">Fibrosarcoma, 91</p>
			<p class="endmatter-idx1">Fibrous dysplasia, 89, 90<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Fibrous histiocytoma, 89</p>
			<p class="endmatter-idx1">Fine-&#173;needle aspiration biopsy (FNAB), 132, 132<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Fistula</p>
			<p class="endmatter-idx2">arteriovenous, 78, 78<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">carotid-&#173;cavernous, 78–79<span class="endmatter-idx2_italic">f</span>, 78–80</p>
			<p class="endmatter-idx2">lacrimal–&#173;cutaneous, 286, 286<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Fitzpatrick skin type, 268</p>
			<p class="endmatter-idx1">FL.&#160;<span class="endmatter-idx1_italic">See</span> Follicular lymphoma</p>
			<p class="endmatter-idx1">FLAIR. <span class="endmatter-idx1_italic">See</span> Fluid-attenuated inversion recovery</p>
			<p class="endmatter-idx1">Flaps</p>
			<p class="endmatter-idx2">Cutler-&#173;Beard, 221, 223<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">eyelid defects reconstructed using, 220</p>
			<p class="endmatter-idx2">modified Hughes, 223–224<span class="endmatter-idx2_italic">f</span>, 224</p>
			<p class="endmatter-idx2">Mustard<span class="endmatter-idx2_accent">é</span>, 224, 225<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Floor of orbit. <span class="endmatter-idx1_italic">See</span> Orbital floor</p>
			<p class="endmatter-idx1">Floppy eyelid syndrome, 184–185, 185<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Fluid-&#173;attenuated inversion recovery (FLAIR), 28</p>
			<p class="endmatter-idx1">FNAB. <span class="endmatter-idx1_italic">See</span> Fine-&#173;needle aspiration biopsy</p>
			<p class="endmatter-idx1">Follicular conjunctivitis, 94, 190, 190<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Follicular keratosis, 188, 188<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Follicular lymphoma (FL), 92, 95</p>
			<p class="endmatter-idx1">Foramen rotundum, 7<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Forced duction test, 114</p>
			<p class="endmatter-idx1">Forehead rejuvenation, 271</p>
			<p class="endmatter-idx1">Foreheadplasty, 265</p>
			<p class="endmatter-idx1">Foreign bodies, intraorbital, 117–118, 118<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Fossa</p>
			<p class="endmatter-idx2">lacrimal gland, 6, 7<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pituitary, 8<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pterygopalatine, 8, 8<span class="endmatter-idx2_italic">f</span>, 10</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">FOXL2</span> gene, 173</p>
			<p class="endmatter-idx1">Fractionated stereotactic radiotherapy, for optic nerve sheath meningioma, 86</p>
			<p class="endmatter-idx1">Freckle. <span class="endmatter-idx1_italic">See</span> Ephelis</p>
			<p class="endmatter-idx1">&#173;Free tarsoconjunctival graft and skin flap, for lower eyelid defects, 223<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Frontal bone</p>
			<p class="endmatter-idx2">anatomy of, 7–8<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pneumatization of, 19</p>
			<p class="endmatter-idx1">Frontal nerve, 14</p>
			<p class="endmatter-idx1">Frontal sinus</p>
			<p class="endmatter-idx2">anatomy of, 8<span class="endmatter-idx2_italic">f</span>, 19<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">development of, 19</p>
			<p class="endmatter-idx1">Frontalis, 153, 154<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Frontalis muscle, 152<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Frontalis suspension, 145, 250, 251<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Frontoethmoidal suture, 7</p>
			<p class="endmatter-idx1">Frontotemporal-&#173;orbitozygomatic (FTOZ) <br />approach, 132</p>
			<p class="endmatter-idx1">Frontozygomatic suture, 6, 7<span class="endmatter-idx1_italic">f</span>, 40, 40<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Frozen section analy&#173;sis, 33</p>
			<p class="endmatter-idx1">FTOZ approach. <span class="endmatter-idx1_italic">See</span> Frontotemporal-&#173;orbitozygomatic (FTOZ) approach</p>
			<p class="endmatter-idx1">Full-&#173;thickness pentagonal resection, for trichiasis, 240</p>
			<p class="endmatter-idx1">Full-&#173;thickness skin grafts</p>
			<p class="endmatter-idx2">for medial canthal defects, 226, 227<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">for upper eyelid defects, 220, 221<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx-alpha">Gadolinium-&#173;enhanced T1-&#173;weighted MRI, 28, 28<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="endmatter-idx1">GAG.&#160;<span class="endmatter-idx1_italic">See</span> Glycosaminoglycans</p>
			<p class="endmatter-idx1">&#173;Giant cell arteritis, 62–63</p>
			<p class="endmatter-idx1">&#173;Giant fornix syndrome, 141</p>
			<p class="endmatter-idx1">&#173;Giant papillary conjunctivitis, 142, 142<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Gland of Krause, 168, 280</p>
			<p class="endmatter-idx1">Gland of Moll, 191</p>
			<p class="endmatter-idx1">Gland of Wolfring, 168, 280</p>
			<p class="endmatter-idx1">Gland of Zeis, 183, 191</p>
			<p class="endmatter-idx1">Globe</p>
			<p class="endmatter-idx2">displacement of, 23–24</p>
			<p class="endmatter-idx2">orbital tumors from, 101</p>
			<p class="endmatter-idx2">palpation of, 25</p>
			<p class="endmatter-idx2">position of, 24</p>
			<p class="endmatter-idx2">ptosis of, 114</p>
			<p class="endmatter-idx1">Globe tenting, 5</p>
			<p class="endmatter-idx1">Glucocorticoids, for thyroid eye disease, 60–61</p>
			<p class="endmatter-idx1">Glycosaminoglycans (GAG), 57</p>
			<p class="endmatter-idx1">Gorlin syndrome, 201, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">GPA.&#160;<span class="endmatter-idx1_italic">See</span> Granulomatosis with polyangiitis</p>
			<p class="endmatter-idx1">Gradient echo sequences, 28–29</p>
			<p class="endmatter-idx1">Granulomatosis with polyangiitis (GPA)</p>
			<p class="endmatter-idx2">description of, 34, 63–64, 64<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">nasolacrimal duct obstruction associated with, <br />306, 306<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Graves disease, 54</p>
			<p class="endmatter-idx1">Graves ophthalmopathy. <span class="endmatter-idx1_italic">See</span> Thyroid eye disease</p>
			<p class="endmatter-idx-alpha">HA-&#173;MRSA. <span class="endmatter-idx-alpha_italic">See</span> Hospital-&#173;associated methicillin-&#173;resistant <span class="endmatter-idx-alpha_italic">Staphylococcus aureus</span></p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Haemophilus influenzae,</span> 46</p>
			<p class="endmatter-idx1">Hair follicle tumors, 193–194</p>
			<p class="endmatter-idx1">Hamartomas, 40</p>
			<p class="endmatter-idx1">Hashimoto thyroiditis, 54, 57</p>
			<p class="endmatter-idx1">Head trauma, 119</p>
			<p class="endmatter-idx1">Helical CT scanners, 27</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Helicobacter pylori,</span> 92</p>
			<p class="endmatter-idx1">Hemangioma, infantile (capillary), 71<span class="endmatter-idx1_italic">f</span>, 71–73, 180–181</p>
			<p class="endmatter-idx1">Hemangiopericytomas, 89</p>
			<p class="endmatter-idx1">Hemifacial microsomia, 27<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Hemifacial spasm (HFS), 256, 257<span class="endmatter-idx1_italic">f</span>, 258, 269</p>
			<p class="endmatter-idx1">Hering’s law of equal innervation, 242, 242<span class="endmatter-idx1_italic">f</span>, 253</p>
			<p class="endmatter-idx1">Herpes simplex virus, 269</p>
			<p class="endmatter-idx1">HFS. <span class="endmatter-idx1_italic">See</span> Hemifacial spasm</p>
			<p class="endmatter-idx1">Hidrocystoma, eccrine, 191</p>
			<p class="endmatter-idx1">Hilar adenopathy, 65<span class="endmatter-idx1_italic">f</span>, 66</p>
			<p class="endmatter-idx1">Histiocytic disorders, 95–97, 96<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Hordeolum, 183–184, 184<span class="endmatter-idx1_italic">f</span>, 191</p>
			<p class="endmatter-idx1">Horner muscle, 163, 282</p>
			<p class="endmatter-idx1">Horner syndrome</p>
			<p class="endmatter-idx2">congenital, 246</p>
			<p class="endmatter-idx2">description of, 104, 243–244</p>
			<p class="endmatter-idx1">Hospital-&#173;associated methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus</span> (HA-MRSA), 45</p>
			<p class="endmatter-idx1">&#173;Human bites, 218</p>
			<p class="endmatter-idx1">Hutchinson melanotic freckle, 200</p>
			<p class="endmatter-idx1">Hyaluronic acid fillers, 270, 270<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Hydraulic mechanism theory, 114</p>
			<p class="endmatter-idx1">Hyperglobus, 23</p>
			<p class="endmatter-idx1">Hypertelorism, 23, 39</p>
			<p class="endmatter-idx1">Hyperthyroidism, radioactive iodine for, 60</p>
			<p class="endmatter-idx1">Hypoglobus, 23</p>
			<p class="endmatter-idx-alpha">IGF-I. <span class="endmatter-idx-alpha_italic">See</span> Insulin-like growth factor I</p>
			<p class="endmatter-idx1">IGF-&#173;IR.&#160;<span class="endmatter-idx-alpha_italic">See</span> Insulin-&#173;like growth &#173;factor I receptor</p>
			<p class="endmatter-idx1">IgG4-&#173;RD.&#160;<span class="endmatter-idx1_italic">See</span> Immunoglobulin G4–&#173;related disease</p>
			<p class="endmatter-idx1">Immune-&#173;checkpoint inhibitors, 206, 210–211</p>
			<p class="endmatter-idx1">Immunoglobulin G4–&#173;related disease (IgG4-&#173;RD), 66<span class="endmatter-idx1_italic">f</span>, 66–67</p>
			<p class="endmatter-idx1">Immunotherapy, for melanoma, 210</p>
			<p class="endmatter-idx1">Implants, orbital</p>
			<p class="endmatter-idx2">description of, 117, 139<span class="endmatter-idx2_italic">f</span>, 139–141</p>
			<p class="endmatter-idx2">exposure and extrusion of, 142<span class="endmatter-idx2_italic">f</span>, 142–143</p>
			<p class="endmatter-idx2">osseointegrated magnetic, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Incisional biopsy, 203, 203<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Indirect (blowout) fractures, 113</p>
			<p class="endmatter-idx1">Indirect carotid-&#173;cavernous fistulas, 79</p>
			<p class="endmatter-idx1">Infantile (capillary) hemangioma, 71<span class="endmatter-idx1_italic">f</span>, 71–73, <br />180–181</p>
			<p class="endmatter-idx1">Infection</p>
			<p class="endmatter-idx2">canaliculitis, 313, 314<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dacryoadenitis, 312–313</p>
			<p class="endmatter-idx2">dacryocystitis, 313–315, 315<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital inflammation caused by. <span class="endmatter-idx2_italic">See</span> Orbital inflammation, infectious &#173;causes of</p>
			<p class="endmatter-idx1">Inferior conchae, 19</p>
			<p class="endmatter-idx1">Inferior oblique muscle, 262</p>
			<p class="endmatter-idx1">Inferior ophthalmic vein, 13<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Inferior orbital fissure, 7–8<span class="endmatter-idx1_italic">f</span>, 9–10, 130<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Inferior orbitotomy</p>
			<p class="endmatter-idx2">transconjunctival incisions for, 126–127, 127<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">transcutaneous incisions for, 126, 126<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Inferior rectus muscle</p>
			<p class="endmatter-idx2">anatomy of, 12, 13<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">hydatid cyst of, 53<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Inferior tarsal muscle, 167</p>
			<p class="endmatter-idx1">Inferior turbinate infracture, 294</p>
			<p class="endmatter-idx1">Inflammation, orbital. <span class="endmatter-idx1_italic">See</span> Orbital inflammation</p>
			<p class="endmatter-idx1">Infraorbital artery, 8</p>
			<p class="endmatter-idx1">Infraorbital canal, 8</p>
			<p class="endmatter-idx1">Infraorbital foramen, 7<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Infraorbital groove, 8</p>
			<p class="endmatter-idx1">Infraorbital nerve, 12<span class="endmatter-idx1_italic">f</span>, 20</p>
			<p class="endmatter-idx1">Insulin-&#173;like growth &#173;factor I (IGF-&#173;I), 56</p>
			<p class="endmatter-idx1">Insulin-&#173;like growth &#173;factor I receptor (IGF-&#173;IR), 57</p>
			<p class="endmatter-idx1">Interleukin-2, 210</p>
			<p class="endmatter-idx1">Intermuscular septum, 12</p>
			<p class="endmatter-idx1">Internal carotid artery, 14, 170</p>
			<p class="endmatter-idx1">Internal hordeolum, 183</p>
			<p class="endmatter-idx1">Internal posterior hordeolum. <span class="endmatter-idx1_italic">See</span> Chalazion</p>
			<p class="endmatter-idx1">Intraconal fat, 12</p>
			<p class="endmatter-idx1">Intraconal surgical space, 124</p>
			<p class="endmatter-idx1">Intracranial hypertension, 80</p>
			<p class="endmatter-idx1">Intraocular melanomas, 146</p>
			<p class="endmatter-idx1">Intraocular pressure, in orbital compartment, 119</p>
			<p class="endmatter-idx1">Intraorbital optic nerve, 11</p>
			<p class="endmatter-idx1">Intubation, lacrimal stent, 292–294, 294<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Invasive aspergillosis, 52</p>
			<p class="endmatter-idx1">Involutional ectropion</p>
			<p class="endmatter-idx2">clinical features of, 230<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">horizontal eyelid laxity as cause of, 231</p>
			<p class="endmatter-idx2">lateral tarsal strip procedure for, 231, 232<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">lower eyelid tightening surgery for, 231, 232<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">medial spindle procedure for, 231, 232<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Involutional entropion</p>
			<p class="endmatter-idx2">&#173;causes of, 234</p>
			<p class="endmatter-idx2">clinical features of, 235<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">retractor disinsertion as cause of, 234–235</p>
			<p class="endmatter-idx2">surgical repair of, 236, 236<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">temporizing mea&#173;sures for, 235<span class="endmatter-idx2_italic">f</span>, 235–236</p>
			<p class="endmatter-idx2">transconjunctival approach to, 236, 236<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Involutional stenosis, 305</p>
			<p class="endmatter-idx1">Ipilimumab, 210</p>
			<p class="endmatter-idx1">Irrigation, of lacrimal drainage system, 291–292, 291–292<span class="endmatter-idx1_italic">f</span>, 297–298, 299–300<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Irritated follicular keratosis, 188, 188<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Jaw-winking syndrome. <span class="endmatter-idx-alpha_italic">See</span> Marcus Gunn jaw-winking ptosis</p>
			<p class="endmatter-idx1">Jones I test, 297</p>
			<p class="endmatter-idx1">Jones II test, 297</p>
			<p class="endmatter-idx1">Jowling, 267</p>
			<p class="endmatter-idx1">Junctional nevus, 196</p>
			<p class="endmatter-idx1">Juvenile xanthogranuloma, 97</p>
			<p class="endmatter-idx-alpha">Kaposi sarcoma, 211, 211<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="endmatter-idx1">Kasabach-&#173;Merritt syndrome, 72</p>
			<p class="endmatter-idx1">Keratoacanthoma, 199–200, 200<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Keratocystic odontogenic tumors, 201</p>
			<p class="endmatter-idx1">Kissing nevus, 196, 197<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Lacerations, eyelid, 214–216<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="endmatter-idx1">Lacrimal artery, 12<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lacrimal bone, 7<span class="endmatter-idx1_italic">f</span>, 8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lacrimal canaliculi. <span class="endmatter-idx1_italic">See</span> Canaliculi, lacrimal</p>
			<p class="endmatter-idx1">Lacrimal crest, 282</p>
			<p class="endmatter-idx1">Lacrimal drainage system</p>
			<p class="endmatter-idx2">abnormalities of</p>
			<p class="endmatter-idx3">developmental, 285–287</p>
			<p class="endmatter-idx3">duplication, 286</p>
			<p class="endmatter-idx2">acquired obstruction of</p>
			<p class="endmatter-idx3">canalicular obstruction, 298, 299<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">diagnostic tests for, 297–300, 298–300<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">evaluation of, 294–300</p>
			<p class="endmatter-idx3">history-&#173;taking for, 294</p>
			<p class="endmatter-idx3">nasolacrimal duct, 305–310</p>
			<p class="endmatter-idx3">physical examination for, 295–296</p>
			<p class="endmatter-idx3">probing for, 298, 300</p>
			<p class="endmatter-idx3">pseudoepiphora, 296</p>
			<p class="endmatter-idx2">anatomy of, 162<span class="endmatter-idx2_italic">f</span>, 281<span class="endmatter-idx2_italic">f</span>, 281–283</p>
			<p class="endmatter-idx2">congenital obstruction of</p>
			<p class="endmatter-idx3">balloon dacryoplasty for, 294</p>
			<p class="endmatter-idx3">canalicular agenesis and dysgenesis, 288</p>
			<p class="endmatter-idx3">dacryocystocele, 289, 290<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">dacryocystorhinostomy for, 295</p>
			<p class="endmatter-idx3">evaluation of, 287–288</p>
			<p class="endmatter-idx3">lacrimal intubation stents for, 292–294, 293–294<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">nasolacrimal duct. <span class="endmatter-idx3_italic">See</span> Nasolacrimal duct obstruction</p>
			<p class="endmatter-idx3">probing and irrigation for, 291–292, 291–292<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">punctal agenesis and dysgenesis, 288</p>
			<p class="endmatter-idx2">defects of, 226</p>
			<p class="endmatter-idx2">development of</p>
			<p class="endmatter-idx3">abnormalities of, 285–287</p>
			<p class="endmatter-idx3">normal, 283</p>
			<p class="endmatter-idx2">diagnostic tests of, 297–300, 298–300<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dye disappearance test of, 297, 298<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">irrigation of, 291–292, 291–292<span class="endmatter-idx2_italic">f</span>, 297–298, 299–300<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">neoplasm of, 316–317</p>
			<p class="endmatter-idx2">outflow examination, 296, 297<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">therapeutic closure of, 310–311</p>
			<p class="endmatter-idx1">Lacrimal fossa, 98. <span class="endmatter-idx1_italic">See also</span> fossa</p>
			<p class="endmatter-idx1">Lacrimal gland</p>
			<p class="endmatter-idx2">agenesis of, 285</p>
			<p class="endmatter-idx2">anatomy of, 279–281, 280<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">canaliculi of. <span class="endmatter-idx2_italic">See</span> Canaliculi, lacrimal</p>
			<p class="endmatter-idx2">congenital abnormalities of, 285</p>
			<p class="endmatter-idx2">drainage system of. <span class="endmatter-idx2_italic">See</span> Lacrimal drainage system</p>
			<p class="endmatter-idx2">fistula of, 285</p>
			<p class="endmatter-idx2">fossa of, 6, 7<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">hypoplasia of, 285</p>
			<p class="endmatter-idx2">infection of, 312–315</p>
			<p class="endmatter-idx2">malignant epithelial tumors of, 146</p>
			<p class="endmatter-idx2">outflow examination, 296, 297<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pump mechanism of, 284, 284<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">puncta of</p>
			<p class="endmatter-idx3">agenesis of, 288</p>
			<p class="endmatter-idx3">anatomy of, 281, 284<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">aplasia, 287, 287<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">dilatation of, 291<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">disorders of, 300–302</p>
			<p class="endmatter-idx3">duplication of, 286</p>
			<p class="endmatter-idx3">dysgenesis of, 288</p>
			<p class="endmatter-idx3">epiphora, 301, 301<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">occlusion of, 300</p>
			<p class="endmatter-idx3">plugs, 302, 306, 310</p>
			<p class="endmatter-idx3">stenosis of, 301</p>
			<p class="endmatter-idx3">thermal obliteration of, 311</p>
			<p class="endmatter-idx2">secretory system of. <span class="endmatter-idx2_italic">See</span> Lacrimal secretory system</p>
			<p class="endmatter-idx2">tumors of</p>
			<p class="endmatter-idx3">adenoid cystic carcinoma, 100</p>
			<p class="endmatter-idx3">description of, 98</p>
			<p class="endmatter-idx3">epithelial, 98–100, 99<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">malignant mixed tumor, 100</p>
			<p class="endmatter-idx3">nonepithelial, 101</p>
			<p class="endmatter-idx3">pleomorphic adenomas, 98–100, 99<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx1">Lacrimal intubation stents, 292–294, 294<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lacrimal nerve, 14</p>
			<p class="endmatter-idx1">Lacrimal plugs, 302, 306</p>
			<p class="endmatter-idx1">Lacrimal sac</p>
			<p class="endmatter-idx2">dacryocystitis findings in, 314</p>
			<p class="endmatter-idx2">description of, 282</p>
			<p class="endmatter-idx2">neoplasm of, 295<span class="endmatter-idx2_italic">f</span>, 316<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">palpation of, 296</p>
			<p class="endmatter-idx2">squamous cell carcinoma of, 316<span class="endmatter-idx2_italic">f</span>, 317</p>
			<p class="endmatter-idx2">traumatic injuries to, 312</p>
			<p class="endmatter-idx2">tumors of, 316–317</p>
			<p class="endmatter-idx1">Lacrimal secretory system</p>
			<p class="endmatter-idx2">anatomy of, 279–281, 280<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">development of</p>
			<p class="endmatter-idx3">abnormalities involving, 285</p>
			<p class="endmatter-idx3">normal, 283</p>
			<p class="endmatter-idx1">Lacrimal vein, 12<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lacrimal–&#173;cutaneous fistula, 286, 286<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lagophthalmos, 242, 246, 255, 263</p>
			<p class="endmatter-idx1">Laherparepvec, 210</p>
			<p class="endmatter-idx1">Lamina papyracea, 7</p>
			<p class="endmatter-idx1">Langerhans cell histiocytosis, 95, 96<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">&#173;Laser skin resurfacing, 268–269</p>
			<p class="endmatter-idx1">Lash margin entropion, 145, 145<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lateral canthal tendon</p>
			<p class="endmatter-idx2">defects of, eyelid reconstruction for, 225, 226–227<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">description of, 169</p>
			<p class="endmatter-idx2">trauma to, 214–215</p>
			<p class="endmatter-idx1">Lateral canthotomy, 117, 119, 124<span class="endmatter-idx1_italic">f</span>, 126, 129, 130, 222<span class="endmatter-idx1_italic">f</span>, 223<span class="endmatter-idx1_italic">f</span>. <span class="endmatter-idx1_italic">See also</span> Canthotomy</p>
			<p class="endmatter-idx1">Lateral orbital tubercle of Whitnall, 6, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lateral rectus muscle, 12, 12<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lateral tarsal strip procedure, 175, 231, 232<span class="endmatter-idx1_italic">f</span>, 233<span class="endmatter-idx1_italic">f</span>, 236</p>
			<p class="endmatter-idx1">Lateral wall of orbit</p>
			<p class="endmatter-idx2">anatomy of, 6</p>
			<p class="endmatter-idx2">decompression of, 130, 131<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Le Fort fractures, 109, 110<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lentigo maligna, 200</p>
			<p class="endmatter-idx1">Lentigo maligna melanoma, 209, 209<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lentigo simplex, 197</p>
			<p class="endmatter-idx1">Levator aponeurosis, 165<span class="endmatter-idx1_italic">f</span>, 165–166</p>
			<p class="endmatter-idx1">Levator palpebrae superioris muscle, 12, 166</p>
			<p class="endmatter-idx1">Lid lag, 23<span class="endmatter-idx1_italic">t</span>, 25, 54<span class="endmatter-idx1_italic">f</span>, 58, 244, 244<span class="endmatter-idx1_italic">f</span>, 245<span class="endmatter-idx1_italic">t</span>. <span class="endmatter-idx1_italic">See also</span> <br />Myogenic ptosis; Thyroid eye disease</p>
			<p class="endmatter-idx1">Liposarcoma, 91</p>
			<p class="endmatter-idx1">Liposuction, neck, 274–275, 275<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">LMs.&#160;<span class="endmatter-idx1_italic">See</span> Lymphatic malformations</p>
			<p class="endmatter-idx1">Lockwood ligament, 165</p>
			<p class="endmatter-idx1">Long ciliary nerves, 14</p>
			<p class="endmatter-idx1">Lower eyelids. <span class="endmatter-idx1_italic">See also</span> Eyelid(s); <span class="endmatter-idx1_italic">specific disorders</span></p>
			<p class="endmatter-idx2">anatomy of, 160<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">arterial arcade of, 171</p>
			<p class="endmatter-idx2">blepharoplasty of</p>
			<p class="endmatter-idx3">infraciliary incision for, 262</p>
			<p class="endmatter-idx3">&#173;laser skin resurfacing with, 268</p>
			<p class="endmatter-idx3">midface rejuvenation with, 271–272, 272<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">orbital fat redraping with, 272<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">technique for, 261–262, 262<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">transconjunctival incision for, 261, 262<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">vision loss secondary to, 262</p>
			<p class="endmatter-idx2">cicatricial entropion of, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">defects involving, reconstruction of, 222–225, 223–224<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">entropion of, 234</p>
			<p class="endmatter-idx2">epiblepharon of, 178<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">hyaluronic acid filler application to, 270<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">laceration of, 217<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">milia of, 189, 189<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital septum, 163</p>
			<p class="endmatter-idx2">retractors of</p>
			<p class="endmatter-idx3">anatomy of, 167, 167<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">surgical repair of, 232, 236<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">sebaceous hyperplasia of, 191<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">squamous cell carcinoma of, 206<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">tightening surgery for, 231, 232<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">transcutaneous incision of, 126<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">xanthelasmas of, 190, 190<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Lower face rejuvenation, 272–273</p>
			<p class="endmatter-idx1">Lymphangiomas, 14. <span class="endmatter-idx1_italic">See also</span> Lymphatic malformations</p>
			<p class="endmatter-idx1">Lymphatic malformations (LMs), 73<span class="endmatter-idx1_italic">f</span>, 73–74</p>
			<p class="endmatter-idx1">Lymphatic system</p>
			<p class="endmatter-idx2">of eyelids, 170–171</p>
			<p class="endmatter-idx2">of orbit, 14</p>
			<p class="endmatter-idx1">Lymphedema, 184, 184<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Lymphoid hyperplasia, 94</p>
			<p class="endmatter-idx1">Lymphoma, orbital</p>
			<p class="endmatter-idx2">diffuse large B-&#173;cell, 92</p>
			<p class="endmatter-idx2">extranodal marginal zone B-&#173;cell, 92, 95</p>
			<p class="endmatter-idx2">follicular, 92, 95</p>
			<p class="endmatter-idx2">malignant, 94</p>
			<p class="endmatter-idx2">mantle cell, 92</p>
			<p class="endmatter-idx2">non-&#173;Hodgkin. <span class="endmatter-idx2_italic">See</span> Non-&#173;Hodgkin lymphoma</p>
			<p class="endmatter-idx1">Lymphoproliferative disorders</p>
			<p class="endmatter-idx2">biopsy of, 94</p>
			<p class="endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 93, 93<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">diagnosis of, 93</p>
			<p class="endmatter-idx2">histiocytic disorders, 95–97, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">management of, 94–95</p>
			<p class="endmatter-idx2">non-&#173;Hodgkin lymphoma. <span class="endmatter-idx2_italic">See</span> Non-&#173;Hodgkin lymphoma</p>
			<p class="endmatter-idx2">plasma cell tumors, 95</p>
			<p class="endmatter-idx2">salmon-&#173;patch subconjunctival lesion, 94<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">xanthogranuloma, 97</p>
			<p class="endmatter-idx1">Lysozyme, 34</p>
			<p class="endmatter-idx-alpha">Macrocystic, 73</p>
			<p class="endmatter-idx1">Madarosis, 187, 202, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Magnetic resonance imaging (MRI)</p>
			<p class="endmatter-idx2">arteriovenous malformations on, 77<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">carotid-&#173;cavernous fistulas on, 78<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">computed tomography versus, 29<span class="endmatter-idx2_italic">t</span>, 29–31</p>
			<p class="endmatter-idx2">contraindications for, 30</p>
			<p class="endmatter-idx2">Erdheim-&#173;Chester disease on, 98<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">ethmoid sinus squamous cell carcinoma on, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fibrous dysplasia on, 89</p>
			<p class="endmatter-idx2">gadolinium-&#173;enhanced T1-&#173;weighted, 28<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">indications for, 300</p>
			<p class="endmatter-idx2">infantile hemangiomas on, 72</p>
			<p class="endmatter-idx2">Langerhans cell histiocytosis on, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">metastatic breast carcinoma on, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">metastatic neuroblastoma on, 105<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">microphthalmia with orbital cysts on, 37<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">optic nerve glioma on, 80–81, 81<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">optic nerve sheath meningioma on, 85<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital cellulitis on, 47<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital disorders on, 27–31, 28<span class="endmatter-idx2_italic">f</span>, 29<span class="endmatter-idx2_italic">t</span>, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">princi&#173;ples of, 27–28</p>
			<p class="endmatter-idx2">rhabdomyosarcoma on, 87, 87<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">solitary fibrous tumor on, 89, 90<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">sphenoid wing meningioma on, 84<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">T1-&#173;weighted, 28<span class="endmatter-idx2_italic">f</span>, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">T2-&#173;weighted, 28<span class="endmatter-idx2_italic">f</span>, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">zygomycosis on, 51<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Magnetic resonance imaging (MRI) angiography, 32, 79</p>
			<p class="endmatter-idx1">Malignant meningioma, 86</p>
			<p class="endmatter-idx1">Malignant mixed tumor, 100</p>
			<p class="endmatter-idx1">MALT. <span class="endmatter-idx1_italic">See</span> Mucosa-&#173;associated lymphoid tissue</p>
			<p class="endmatter-idx1">Mandibulofacial dysostosis, 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Mantle cell lymphoma (MCL), 92</p>
			<p class="endmatter-idx1">Marcus Gunn jaw-&#173;winking ptosis, 243, 246, 247<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Marginal arterial arcade, 171</p>
			<p class="endmatter-idx1">Marginal cicatricial entropion, 239</p>
			<p class="endmatter-idx1">Marginal entropion, 238</p>
			<p class="endmatter-idx1">Margin–&#173;reflex distance 1 (MRD<span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span>), 241–242</p>
			<p class="endmatter-idx1">Margin–&#173;reflex distance 2 (MRD<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>), 242</p>
			<p class="endmatter-idx1">Marsupialization, of chalazion, 182</p>
			<p class="endmatter-idx1">Mass casualty incidents (MCIs), 122</p>
			<p class="endmatter-idx1">Maxillary bone, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Maxillary nerve, 10</p>
			<p class="endmatter-idx1">Maxillary sinus, 8<span class="endmatter-idx1_italic">f</span>, 20</p>
			<p class="endmatter-idx1">MCIs.&#160;<span class="endmatter-idx1_italic">See</span> Mass casualty incidents</p>
			<p class="endmatter-idx1">MCL.&#160;<span class="endmatter-idx1_italic">See</span> Mantle cell lymphoma</p>
			<p class="endmatter-idx1">Mechanical epilation, 239</p>
			<p class="endmatter-idx1">Mechanical ptosis, 248, 248<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Medial canthal fold, 176</p>
			<p class="endmatter-idx1">Medial canthal tendon</p>
			<p class="endmatter-idx2">anatomy of, 168–169, 282</p>
			<p class="endmatter-idx2">avulsion of, 215</p>
			<p class="endmatter-idx2">defects of, eyelid reconstruction for, 226, 227<span class="endmatter-idx2_italic">f</span>, 228</p>
			<p class="endmatter-idx2">lower limb laxity, 231</p>
			<p class="endmatter-idx2">repositioning of, 174</p>
			<p class="endmatter-idx2">trauma to, 214–215</p>
			<p class="endmatter-idx1">Medial orbital fractures, 112–114</p>
			<p class="endmatter-idx1">Medial orbitotomy</p>
			<p class="endmatter-idx2">description of, 113, 127</p>
			<p class="endmatter-idx2">retrocaruncular incision for, 128–129<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">transconjunctival incisions for, 128</p>
			<p class="endmatter-idx2">transcutaneous incisions for, 128</p>
			<p class="endmatter-idx1">Medial rectus muscle, 12–13<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Medial spindle procedure, 231, 232<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Meibomian glands</p>
			<p class="endmatter-idx2">anatomy of, 170, 182</p>
			<p class="endmatter-idx2">hordeolum of, 183</p>
			<p class="endmatter-idx2">lesions of, 191</p>
			<p class="endmatter-idx1">Melanocytes, 195</p>
			<p class="endmatter-idx1">Melanocytic lesions</p>
			<p class="endmatter-idx2">benign</p>
			<p class="endmatter-idx3">blue nevi, 198</p>
			<p class="endmatter-idx3">dermal melanocytosis, 198, 198<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">ephelis, 197</p>
			<p class="endmatter-idx3">lentigo simplex, 197</p>
			<p class="endmatter-idx3">nevi, 195–197, 196–197<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">solar lentigo, 197–198, 198<span class="endmatter-idx3_italic">f</span>, 200</p>
			<p class="endmatter-idx3">sources of, 194–195</p>
			<p class="endmatter-idx2">classification of, 195<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">premalignant, 200</p>
			<p class="endmatter-idx1">Melanoma</p>
			<p class="endmatter-idx2">eyelid, 208–211, 209<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">lentigo maligna, 209, 209<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">nodular, 209–210</p>
			<p class="endmatter-idx2">treatment of, 210–211</p>
			<p class="endmatter-idx1">Melasma, 195</p>
			<p class="endmatter-idx1">Meningiomas, 84–85<span class="endmatter-idx1_italic">f</span>, 84–86</p>
			<p class="endmatter-idx1">Meningocele, 38</p>
			<p class="endmatter-idx1">Meningoencephalocele, 39</p>
			<p class="endmatter-idx1">Merkel cells/Merkel cell carcinoma, 212, 212<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Mesenchymal tumors</p>
			<p class="endmatter-idx2">chondrosarcoma, 91</p>
			<p class="endmatter-idx2">fibrosarcoma, 91</p>
			<p class="endmatter-idx2">fibrous dysplasia, 89, 90<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fibrous histiocytoma, 89</p>
			<p class="endmatter-idx2">liposarcoma, 91</p>
			<p class="endmatter-idx2">malignant, 91</p>
			<p class="endmatter-idx2">miscellaneous, 89–91, 90–91<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">osteomas, 89, 91, 91<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">osteosarcoma, 91</p>
			<p class="endmatter-idx2">rhabdomyosarcoma, 87<span class="endmatter-idx2_italic">f</span>, 87–89</p>
			<p class="endmatter-idx2">solitary fibrous tumor, 89, 90<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Metastatic tumors, of orbit</p>
			<p class="endmatter-idx2">in adults, 105–107</p>
			<p class="endmatter-idx2">from breast carcinoma, 106, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">from bronchogenic carcinoma, 106</p>
			<p class="endmatter-idx2">in &#173;children, 104–105</p>
			<p class="endmatter-idx2">leukemia, 104</p>
			<p class="endmatter-idx2">management of, 107</p>
			<p class="endmatter-idx2">neuroblastoma, in &#173;children, 22<span class="endmatter-idx2_italic">f</span>, 104, 105<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus</span> (MRSA)</p>
			<p class="endmatter-idx2">dacryoadenitis caused by, 313</p>
			<p class="endmatter-idx2">orbital cellulitis caused by, 48</p>
			<p class="endmatter-idx2">preseptal cellulitis caused by, 45</p>
			<p class="endmatter-idx1">MG.&#160;<span class="endmatter-idx1_italic">See</span> Myasthenia gravis</p>
			<p class="endmatter-idx1">Microcystic, 73</p>
			<p class="endmatter-idx1">Microphthalmia, 36–38, 136</p>
			<p class="endmatter-idx1">&#173;Middle conchae, 19</p>
			<p class="endmatter-idx1">&#173;Middle lamellar deficiency, 254</p>
			<p class="endmatter-idx1">Midface</p>
			<p class="endmatter-idx2">fractures of, 109, 110<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">rejuvenation of, 271–272, 273<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Milia, 189, 189<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Mimetic muscles, of face, 153, 154<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Mixed macrocystic/microcystic, 73</p>
			<p class="endmatter-idx1">Modified Hughes flaps, 223–224<span class="endmatter-idx1_italic">f</span>, 224</p>
			<p class="endmatter-idx1">Mohs micrographic surgery, 204–207, 228</p>
			<p class="endmatter-idx1">Molluscum contagiosum, 190</p>
			<p class="endmatter-idx1">Monocular elevation deficiency, 245</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Moraxella catarrhalis,</span> 46</p>
			<p class="endmatter-idx1">Morpheaform basal cell carcinoma, 202, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">MPO-&#173;ANCA. <span class="endmatter-idx1_italic">See</span> Myeloperoxidase-&#173;antineutrophil cytoplasmic autoantibody</p>
			<p class="endmatter-idx1">MRD<span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span>. <span class="endmatter-idx1_italic">See</span> Margin–&#173;reflex distance 1</p>
			<p class="endmatter-idx1">MRD<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>. <span class="endmatter-idx1_italic">See</span> Margin–&#173;reflex distance 2</p>
			<p class="endmatter-idx1">MRI.&#160;<span class="endmatter-idx1_italic">See</span> Magnetic resonance imaging</p>
			<p class="endmatter-idx1">MRI angiography. <span class="endmatter-idx1_italic">See</span> Magnetic resonance imaging (MRI) angiography</p>
			<p class="endmatter-idx1">MRSA. <span class="endmatter-idx1_italic">See</span> Methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus</span></p>
			<p class="endmatter-idx1">MTS.&#160;<span class="endmatter-idx1_italic">See</span> Muir-&#173;Torre syndrome</p>
			<p class="endmatter-idx1">Mucoceles, 101–102, 102<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Mucopyoceles, 101</p>
			<p class="endmatter-idx1">Mucormycosis, 51</p>
			<p class="endmatter-idx1">Mucosa-&#173;associated lymphoid tissue (MALT), 92</p>
			<p class="endmatter-idx1">Muir-&#173;Torre syndrome (MTS), 191, 207</p>
			<p class="endmatter-idx1">M<span class="endmatter-idx1_accent">ü</span>ller muscle, 166, 167<span class="endmatter-idx1_italic">f</span>, 171, 254</p>
			<p class="endmatter-idx1">M<span class="endmatter-idx1_accent">ü</span>ller muscle–&#173;conjunctival resection, 145, 250</p>
			<p class="endmatter-idx1">Multicentric basal cell carcinoma, 203</p>
			<p class="endmatter-idx1">Multiple myeloma, 95</p>
			<p class="endmatter-idx1">Muscle of Riolan, 163, 163<span class="endmatter-idx1_italic">f</span>, 170</p>
			<p class="endmatter-idx1">Muscle relaxants and sedatives, for benign essential blepharospasm, 258</p>
			<p class="endmatter-idx1">Mustard<span class="endmatter-idx1_accent">é</span> flap, 224, 225<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Myasthenia gravis (MG)</p>
			<p class="endmatter-idx2">description of, 58</p>
			<p class="endmatter-idx2">ocular, 248</p>
			<p class="endmatter-idx2">ptosis associated with, 244, 247–248</p>
			<p class="endmatter-idx1">Mycobacterial infection, 50, 50<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacterium chelonae,</span> 50</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacterium fortuitum,</span> 50</p>
			<p class="endmatter-idx1">Myectomy, surgical, 257–258</p>
			<p class="endmatter-idx1">Myeloperoxidase-&#173;antineutrophil cytoplasmic <br />autoantibody (MPO-&#173;ANCA), 64</p>
			<p class="endmatter-idx1">Myogenic ptosis, 240, 244<span class="endmatter-idx1_italic">f</span>, 244–245</p>
			<p class="endmatter-idx1">Myositis, 68, 69<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Na<span class="endmatter-idx-alpha_symbol_superscript _idGenCharOverride-1">+</span>/I symporter (NIS), 282, 307</p>
			<p class="endmatter-idx1">Nasal bone, 7<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Nasal cavity, 19</p>
			<p class="endmatter-idx1">Naso-&#173;orbital fractures, 306</p>
			<p class="endmatter-idx1">Naso-&#173;orbito-&#173;ethmoidal (NOE) fractures, 112, 113<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Nasociliary nerve, 12–13<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Nasolabial folds, 270<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Nasolacrimal canal, 11, 20</p>
			<p class="endmatter-idx1">Nasolacrimal duct (NLD)</p>
			<p class="endmatter-idx2">anatomy of, 19, 283</p>
			<p class="endmatter-idx2">canalization of, 283</p>
			<p class="endmatter-idx2">development of, 283</p>
			<p class="endmatter-idx2">imperforate, 288</p>
			<p class="endmatter-idx2">physiology of, 283</p>
			<p class="endmatter-idx2">probing of, 292</p>
			<p class="endmatter-idx2">traumatic injuries to, 312</p>
			<p class="endmatter-idx1">Nasolacrimal duct obstruction (NLDO)</p>
			<p class="endmatter-idx2">complete, 298</p>
			<p class="endmatter-idx2">congenital</p>
			<p class="endmatter-idx3">balloon dacryoplasty for, 294</p>
			<p class="endmatter-idx3">canalicular obstruction, 298, 300<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">&#173;causes of, 283, 287–288</p>
			<p class="endmatter-idx3">dacryocystitis associated with, 289</p>
			<p class="endmatter-idx3">diagnosis of, 300</p>
			<p class="endmatter-idx3">evaluation, 287–288</p>
			<p class="endmatter-idx3">lacrimal intubation stents for, 292–294, 294<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">lacrimal sac palpation in examination for, 296</p>
			<p class="endmatter-idx3">management of, 288–289</p>
			<p class="endmatter-idx3">probing for, 289, 291<span class="endmatter-idx3_italic">f</span>, 291–292, 298, 300</p>
			<p class="endmatter-idx3">treatment of, 287</p>
			<p class="endmatter-idx3">turbinate infracture for, 294</p>
			<p class="endmatter-idx3">valve of Hasner in, 288–289</p>
			<p class="endmatter-idx2">dacryocystitis associated with, 313–315, 315<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dacryocystorhinostomy for, 307–310, 308–309<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dacryolith as cause of, 305<span class="endmatter-idx2_italic">f</span>, 305–306</p>
			<p class="endmatter-idx2">description of, 300</p>
			<p class="endmatter-idx2">diagnosis of, 305</p>
			<p class="endmatter-idx2">endoscopic lacrimal duct recanalization for, 310</p>
			<p class="endmatter-idx2">etiology of, 305–307</p>
			<p class="endmatter-idx2">granulomatosis with polyangiitis as cause of, 306, 306<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">inflammatory diseases as cause of, 306</p>
			<p class="endmatter-idx2">intubation and stenting for, 292–294, <br />294<span class="endmatter-idx2_italic">f</span>, 307</p>
			<p class="endmatter-idx2">involutional stenosis as cause of, 305</p>
			<p class="endmatter-idx2">lacrimal plugs as cause of, 306</p>
			<p class="endmatter-idx2">lacrimal–&#173;cutaneous fistula and, 286</p>
			<p class="endmatter-idx2">management of, 307–310</p>
			<p class="endmatter-idx2">nasal disease as cause of, 306</p>
			<p class="endmatter-idx2">neoplasms as cause of, 307</p>
			<p class="endmatter-idx2">radioactive iodine as cause of, 307</p>
			<p class="endmatter-idx2">sinus disease as cause of, 306</p>
			<p class="endmatter-idx2">traumatic &#173;causes of, 306</p>
			<p class="endmatter-idx1">Naugle exophthalmometer, 24, 24<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">NBX.&#160;<span class="endmatter-idx1_italic">See</span> Necrobiotic xanthogranuloma</p>
			<p class="endmatter-idx1">Neck rejuvenation</p>
			<p class="endmatter-idx2">cervicoplasty, 276<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">liposuction, 274–275, 275<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">platysmaplasty, 276, 276<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Necrobiotic xanthogranuloma (NBX), 97</p>
			<p class="endmatter-idx1">Necrotizing fasciitis, 48–50, 49<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Neoplasms</p>
			<p class="endmatter-idx2">canalicular obstruction caused by, 303</p>
			<p class="endmatter-idx2">eyelid. <span class="endmatter-idx2_italic">See</span> Eyelid neoplasms and tumors</p>
			<p class="endmatter-idx2">lacrimal drainage system, 316–317</p>
			<p class="endmatter-idx2">lacrimal sac, 295<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">metastasis of, 316</p>
			<p class="endmatter-idx2">nasolacrimal duct obstruction caused by, 307</p>
			<p class="endmatter-idx1">Neural tumors</p>
			<p class="endmatter-idx2">meningiomas, 84–85<span class="endmatter-idx2_italic">f</span>, 84–86</p>
			<p class="endmatter-idx2">neurofibroma, 83<span class="endmatter-idx2_italic">f</span>, 83–84</p>
			<p class="endmatter-idx2">optic nerve glioma. <span class="endmatter-idx2_italic">See</span> Optic nerve glioma</p>
			<p class="endmatter-idx2">schwannoma, 86–87</p>
			<p class="endmatter-idx1">Neurilemomas, 86</p>
			<p class="endmatter-idx1">Neuroblastoma, metastatic, 22<span class="endmatter-idx1_italic">f</span>, 104, 105<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Neurofibroma, 83<span class="endmatter-idx1_italic">f</span>, 83–84</p>
			<p class="endmatter-idx1">Neurofibromatosis (NF), 80</p>
			<p class="endmatter-idx1">Neurofibromatosis 1 (NF1), 83–84</p>
			<p class="endmatter-idx1">Neurogenic ptosis</p>
			<p class="endmatter-idx2">acquired, 246–248</p>
			<p class="endmatter-idx2">congenital, 246</p>
			<p class="endmatter-idx2">myasthenia gravis as cause of, 247–248</p>
			<p class="endmatter-idx2">temporary, 247</p>
			<p class="endmatter-idx1">Neurogenic vision loss, 119</p>
			<p class="endmatter-idx1">Nevus, 195–197, 196<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Nevus cells, 195</p>
			<p class="endmatter-idx1">Nevus of Ota, 198, 198<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">NF.&#160;<span class="endmatter-idx1_italic">See</span> Neurofibromatosis</p>
			<p class="endmatter-idx1">NF1. <span class="endmatter-idx1_italic">See</span> Neurofibromatosis 1</p>
			<p class="endmatter-idx1">NF-&#173;<span class="endmatter-idx1_symbol">κ</span>B. <span class="endmatter-idx1_italic">See</span> Nuclear &#173;factor <span class="endmatter-idx1_symbol">κ</span>B</p>
			<p class="endmatter-idx1">NHL. <span class="endmatter-idx1_italic">See</span> Non-Hodgkin lymphoma</p>
			<p class="endmatter-idx1">NIS.&#160;<span class="endmatter-idx1_italic">See</span> Na<span class="endmatter-idx1_symbol_superscript _idGenCharOverride-1">+</span>/I symporter</p>
			<p class="endmatter-idx1">Nivolumab, 210</p>
			<p class="endmatter-idx1">NLD.&#160;<span class="endmatter-idx1_italic">See</span> Nasolacrimal duct</p>
			<p class="endmatter-idx1">NLDO. <span class="endmatter-idx1_italic">See</span> Nasolacrimal duct obstruction</p>
			<p class="endmatter-idx1">Nodular melanoma, 209–210</p>
			<p class="endmatter-idx1">NOE fractures. <span class="endmatter-idx1_italic">See</span> Naso-orbito-ethmoidal (NOE) fractures</p>
			<p class="endmatter-idx1">Non-&#173;Hodgkin lymphoma (NHL)</p>
			<p class="endmatter-idx2">description of, 91–92</p>
			<p class="endmatter-idx2">risk for, 92</p>
			<p class="endmatter-idx1">Noncaseating granuloma, 65</p>
			<p class="endmatter-idx1">Nonspecific orbital inflammation (NSOI)</p>
			<p class="endmatter-idx2">corticosteroids for, 69–70</p>
			<p class="endmatter-idx2">description of, 22, 24</p>
			<p class="endmatter-idx2">diagnosis of, 68–70</p>
			<p class="endmatter-idx2">pathogenesis of, 67</p>
			<p class="endmatter-idx2">sclerosing, 70</p>
			<p class="endmatter-idx2">symptoms of, 68</p>
			<p class="endmatter-idx2">treatment of, 70</p>
			<p class="endmatter-idx1">Nontuberculous (aty&#173;pi&#173;cal) mycobacteria, 50, 50<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Nose</p>
			<p class="endmatter-idx2">anatomy of, 19, 282<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">bony projections of, 19</p>
			<p class="endmatter-idx2">physical examination of, 296</p>
			<p class="endmatter-idx1">NSOI. <span class="endmatter-idx1_italic">See</span> Nonspecific orbital inflammation</p>
			<p class="endmatter-idx1">Nuclear factor &#173;<span class="endmatter-idx1_symbol">κ</span>B (NF-&#173;<span class="endmatter-idx1_symbol">κ</span>B), 92</p>
			<p class="endmatter-idx-alpha">OCS.&#160;<span class="endmatter-idx-alpha_italic">See</span> Orbital compartment syndrome</p>
			<p class="endmatter-idx1">Ocular adnexa</p>
			<p class="endmatter-idx2">lesions of, 190–194, 191–192<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">lymphoproliferative lesions of, 91</p>
			<p class="endmatter-idx1">Ocular myasthenia gravis, 248</p>
			<p class="endmatter-idx1">Oculodermal melanocytosis, 198, 199<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Oculomotor foramen, 13</p>
			<p class="endmatter-idx1">Oculomotor nerve</p>
			<p class="endmatter-idx2">congenital palsy of, 246</p>
			<p class="endmatter-idx2">extraocular muscle innervation by, 12</p>
			<p class="endmatter-idx2">palsy of, 246–247</p>
			<p class="endmatter-idx1">Odontogenic cysts, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Odontogenic infections, 48</p>
			<p class="endmatter-idx1">Oncolytic virus therapy, for melanoma, 210</p>
			<p class="endmatter-idx1">Open reduction and fixation, for zygomatic fractures, 111</p>
			<p class="endmatter-idx1">Ophthalmia, sympathetic. <span class="endmatter-idx1_italic">See</span> Sympathetic ophthalmia</p>
			<p class="endmatter-idx1">Ophthalmic artery</p>
			<p class="endmatter-idx2">anatomy of, 12–13<span class="endmatter-idx2_italic">f</span>, 14, 15–16<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">occlusion of, 157</p>
			<p class="endmatter-idx1">Ophthalmic vein, 13<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Optic canal</p>
			<p class="endmatter-idx2">anatomy of, 7–8<span class="endmatter-idx2_italic">f</span>, 11</p>
			<p class="endmatter-idx2">medial wall of, 7</p>
			<p class="endmatter-idx1">Optic foramen, 11</p>
			<p class="endmatter-idx1">Optic nerve</p>
			<p class="endmatter-idx2">anatomy of, 12–13<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">intraorbital portion of, 11</p>
			<p class="endmatter-idx1">Optic nerve glioma</p>
			<p class="endmatter-idx2">chemotherapy for, 82–83</p>
			<p class="endmatter-idx2">clinical features of, 80</p>
			<p class="endmatter-idx2">diagnosis of, 80–82</p>
			<p class="endmatter-idx2">malignant, 82</p>
			<p class="endmatter-idx2">management of, 82–83</p>
			<p class="endmatter-idx2">surgical excision of, 82</p>
			<p class="endmatter-idx1">Optic nerve sheath meningioma, 85<span class="endmatter-idx1_italic">f</span>, 86</p>
			<p class="endmatter-idx1">Optic strut, 7<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Orbicularis oculi muscle</p>
			<p class="endmatter-idx2">anatomy of, 153, 154<span class="endmatter-idx2_italic">f</span>, 157<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital, 163</p>
			<p class="endmatter-idx2">preseptal, 163</p>
			<p class="endmatter-idx2">pretarsal, 161</p>
			<p class="endmatter-idx2">segments of, 161–163, 162<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Orbit. <span class="endmatter-idx1_italic">See also under Orbital</span></p>
			<p class="endmatter-idx2">bacterial infections of, 43</p>
			<p class="endmatter-idx2">blood supply to, 14, 15–16<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">bones of</p>
			<p class="endmatter-idx3">anatomy of, 6, 7–8<span class="endmatter-idx3_italic">f</span>, 130<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">congenital clefts in, 38</p>
			<p class="endmatter-idx2">computed tomography of, 26<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dimensions of, 5, 6<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">emphysema of, 115</p>
			<p class="endmatter-idx2">extranodal disease of, 92</p>
			<p class="endmatter-idx2">inflammation of. <span class="endmatter-idx2_italic">See</span> Orbital inflammation</p>
			<p class="endmatter-idx2">lymphatic system of, 14</p>
			<p class="endmatter-idx2">nerves of, 14, 17, 18<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">roof of</p>
			<p class="endmatter-idx3">anatomy of, 6</p>
			<p class="endmatter-idx3">fractures of, 112</p>
			<p class="endmatter-idx2">septa of, 12, 12<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">sinus diseases that affect, 101–104, 102–103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">soft tissues of, 11–18</p>
			<p class="endmatter-idx2">surgical spaces in, 123<span class="endmatter-idx2_italic">f</span>, 123–124</p>
			<p class="endmatter-idx2">tissue expanders in, 36</p>
			<p class="endmatter-idx2">topographic relationships of, 6–8, 7–8<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">vasculature of, 14, 15–16<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">walls of</p>
			<p class="endmatter-idx3">apertures of, 9–11, 10<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">bones of, 6, 7–8<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">lateral, 6, 130, 131<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">medial, 7–8</p>
			<p class="endmatter-idx1">Orbital apex</p>
			<p class="endmatter-idx2">anatomy of, 9, 10<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fractures of, 112</p>
			<p class="endmatter-idx1">Orbital apex syndrome, 51</p>
			<p class="endmatter-idx1">Orbital cellulitis, 46<span class="endmatter-idx1_italic">t</span>, 46–48, 47<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Orbital compartment syndrome (OCS), 118–119, <br />120<span class="endmatter-idx1_italic">f</span>, 133</p>
			<p class="endmatter-idx1">Orbital cysts, microphthalmia with, 37<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Orbital decompression</p>
			<p class="endmatter-idx2">definition of, 130</p>
			<p class="endmatter-idx2">description of, 61–62</p>
			<p class="endmatter-idx2">of lateral wall, 130, 131<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital compartment syndrome treated with, <br />119</p>
			<p class="endmatter-idx2">techniques for, 130–131</p>
			<p class="endmatter-idx2">thyroid eye disease treated with, 130, 131<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Orbital disorders</p>
			<p class="endmatter-idx2">arteriography of, 32</p>
			<p class="endmatter-idx2">cell-&#173;marker studies for, 33–34</p>
			<p class="endmatter-idx2">computed tomography angiography of, 32</p>
			<p class="endmatter-idx2">computed tomography of, 26<span class="endmatter-idx2_italic">f</span>, 26–27</p>
			<p class="endmatter-idx2">congenital</p>
			<p class="endmatter-idx3">anophthalmia. <span class="endmatter-idx3_italic">See</span> Anophthalmia</p>
			<p class="endmatter-idx3">craniofacial clefts, 38–39</p>
			<p class="endmatter-idx3">microphthalmia, 36–38</p>
			<p class="endmatter-idx3">overview of, 35</p>
			<p class="endmatter-idx3">syndromic craniosynostosis, 39, 39<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">tumors, 40–42</p>
			<p class="endmatter-idx2">globe displacement associated with, 23–24</p>
			<p class="endmatter-idx2">history-&#173;taking for, 21–22</p>
			<p class="endmatter-idx2">inspection of, 23–25</p>
			<p class="endmatter-idx2">laboratory studies for, 34</p>
			<p class="endmatter-idx2">magnetic resonance imaging of, 27–31, 28<span class="endmatter-idx2_italic">f</span>, 29<span class="endmatter-idx2_italic">t</span>, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pain associated with, 21, 133</p>
			<p class="endmatter-idx2">palpation of, 25–26</p>
			<p class="endmatter-idx2">pathology of, 33–34</p>
			<p class="endmatter-idx2">periorbital changes associated with, 22, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">physical examination of, 22–26</p>
			<p class="endmatter-idx2">progression of, 22</p>
			<p class="endmatter-idx2">stereotactic navigation of, 32, 33<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">ultrasonography of, 31</p>
			<p class="endmatter-idx2">venography of, 32</p>
			<p class="endmatter-idx1">Orbital fat</p>
			<p class="endmatter-idx2">anatomy of, 164, 164<span class="endmatter-idx2_italic">f</span>, 214</p>
			<p class="endmatter-idx2">redraping of, with lower eyelid blepharoplasty, 272<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">trauma to, 214, 214<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Orbital fistulas, 78–79<span class="endmatter-idx1_italic">f</span>, 78–80</p>
			<p class="endmatter-idx1">Orbital floor</p>
			<p class="endmatter-idx2">anatomy of, 8, 9<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fractures of</p>
			<p class="endmatter-idx3">in &#173;children, 115, 116<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">diagnosis of, 114–115</p>
			<p class="endmatter-idx3">hydraulic mechanism theory of, 114</p>
			<p class="endmatter-idx3">management of, 115–117</p>
			<p class="endmatter-idx3">physical examination findings, 114–115</p>
			<p class="endmatter-idx3">surgical management of, 115–117</p>
			<p class="endmatter-idx1">Orbital foramen, 130<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Orbital fractures</p>
			<p class="endmatter-idx2">apex, 112</p>
			<p class="endmatter-idx2">blowout. <span class="endmatter-idx2_italic">See</span> Blowout fractures, orbital</p>
			<p class="endmatter-idx2">floor. <span class="endmatter-idx2_italic">See</span> Orbital floor, fractures of</p>
			<p class="endmatter-idx2">Le Fort, 109, 110<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">medial, 112–114</p>
			<p class="endmatter-idx2">midfacial, 109, 110<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">naso-&#173;orbito-&#173;ethmoidal fractures, 112, 113<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">roof, 112</p>
			<p class="endmatter-idx2">surgical management of, 117</p>
			<p class="endmatter-idx2">zygomatic, 109, 111, 111<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Orbital hemorrhage, 80, 80<span class="endmatter-idx1_italic">f</span>, 262</p>
			<p class="endmatter-idx1">Orbital implants</p>
			<p class="endmatter-idx2">description of, 117, 139<span class="endmatter-idx2_italic">f</span>, 139–141</p>
			<p class="endmatter-idx2">exposure and extrusion of, 142<span class="endmatter-idx2_italic">f</span>, 142–143</p>
			<p class="endmatter-idx2">osseointegrated magnetic, 147<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Orbital inflammation</p>
			<p class="endmatter-idx2">differential diagnosis of, 44<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">infectious &#173;causes of</p>
			<p class="endmatter-idx3">aspergillosis, 52</p>
			<p class="endmatter-idx3">cellulitis. <span class="endmatter-idx3_italic">See</span> Cellulitis</p>
			<p class="endmatter-idx3">mycobacterial infection, 50, 50<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">necrotizing fasciitis, 48–50, 49<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">zygomycosis, 51–52</p>
			<p class="endmatter-idx2">noninfectious &#173;causes of</p>
			<p class="endmatter-idx3">&#173;giant cell arteritis, 62–63</p>
			<p class="endmatter-idx3">granulomatosis with polyangiitis, 63–64, 64<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">immunoglobulin G4–&#173;related disease, 66<span class="endmatter-idx3_italic">f</span>, 66–67</p>
			<p class="endmatter-idx3">polyarteritis nodosa, 65</p>
			<p class="endmatter-idx3">sarcoidosis, 65<span class="endmatter-idx3_italic">f</span>, 65–66</p>
			<p class="endmatter-idx3">thyroid eye disease. <span class="endmatter-idx3_italic">See</span> Thyroid eye disease</p>
			<p class="endmatter-idx3">vasculitis, 62–66, 64–65<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">nonspecific. <span class="endmatter-idx2_italic">See</span> Nonspecific orbital inflammation</p>
			<p class="endmatter-idx2">parasitic &#173;causes of, 53</p>
			<p class="endmatter-idx1">Orbital lesions, 26, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Orbital malformations</p>
			<p class="endmatter-idx2">arteriovenous malformations, 77<span class="endmatter-idx2_italic">f</span>, 77–78</p>
			<p class="endmatter-idx2">cavernous venous malformations, 75–77, 76<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">distensible venous malformations, 74–75, 75<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">lymphatic malformation, 73<span class="endmatter-idx2_italic">f</span>, 73–74</p>
			<p class="endmatter-idx1">Orbital mass, 25</p>
			<p class="endmatter-idx1">Orbital metastases</p>
			<p class="endmatter-idx2">in adults, 105–107</p>
			<p class="endmatter-idx2">from breast carcinoma, 106, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">from bronchogenic carcinoma, 106</p>
			<p class="endmatter-idx2">in &#173;children, 104–105</p>
			<p class="endmatter-idx2">leukemia, 104</p>
			<p class="endmatter-idx2">management of, 107</p>
			<p class="endmatter-idx2">neuroblastoma, in &#173;children, 22<span class="endmatter-idx2_italic">f</span>, 104, 105<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Orbital surgery. <span class="endmatter-idx1_italic">See also</span> Surgery</p>
			<p class="endmatter-idx2">complications of, 133</p>
			<p class="endmatter-idx2">decompression. <span class="endmatter-idx2_italic">See</span> Orbital decompression</p>
			<p class="endmatter-idx2">entry sites for, 124<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fine-&#173;needle aspiration biopsy, 132, 132<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbitotomy. <span class="endmatter-idx2_italic">See</span> Orbitotomy</p>
			<p class="endmatter-idx2">postoperative care for, 131</p>
			<p class="endmatter-idx2">spaces of, 123<span class="endmatter-idx2_italic">f</span>, 123–124</p>
			<p class="endmatter-idx2">special techniques in orbit, 132<span class="endmatter-idx2_italic">f</span>, 132–133</p>
			<p class="endmatter-idx1">Orbital trauma</p>
			<p class="endmatter-idx2">battlefield-&#173;related, 122</p>
			<p class="endmatter-idx2">cerebrospinal fluid leakage &#173;after, 184</p>
			<p class="endmatter-idx2">foreign bodies, 117–118, 118<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">fractures. <span class="endmatter-idx2_italic">See</span> Orbital fractures</p>
			<p class="endmatter-idx2">mass casualty incidents, 122</p>
			<p class="endmatter-idx2">vision loss with clear media, 119, 121</p>
			<p class="endmatter-idx1">Orbital tuberculosis, 50</p>
			<p class="endmatter-idx1">Orbital tumors</p>
			<p class="endmatter-idx2">choristomas, 40</p>
			<p class="endmatter-idx2">congenital, 40–42, 42<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dermoid cyst, 40–41</p>
			<p class="endmatter-idx2">dermolipoma, 41, 42<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">hamartomas, 40</p>
			<p class="endmatter-idx2">infantile (capillary) hemangioma, 71<span class="endmatter-idx2_italic">f</span>, 71–73</p>
			<p class="endmatter-idx2">mesenchymal. <span class="endmatter-idx2_italic">See</span> Mesenchymal tumors</p>
			<p class="endmatter-idx2">metastatic. <span class="endmatter-idx2_italic">See</span> Orbital metastases</p>
			<p class="endmatter-idx2">neural. <span class="endmatter-idx2_italic">See</span> Neural tumors</p>
			<p class="endmatter-idx2">secondary, 101–104</p>
			<p class="endmatter-idx2">teratoma, 42</p>
			<p class="endmatter-idx1">Orbital varices, 74</p>
			<p class="endmatter-idx1">Orbitotomy</p>
			<p class="endmatter-idx2">hemostasis &#173;after, 130</p>
			<p class="endmatter-idx2">inferior approach</p>
			<p class="endmatter-idx3">transconjunctival incisions for, 126–127, 127<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">transcutaneous incisions for, 126, 126<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">lateral approach, 128–130, 129<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">medial approach</p>
			<p class="endmatter-idx3">description of, 127</p>
			<p class="endmatter-idx3">retrocaruncular incision for, 128–129<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">transconjunctival incisions for, 128</p>
			<p class="endmatter-idx3">transcutaneous incisions for, 128</p>
			<p class="endmatter-idx2">superior approach</p>
			<p class="endmatter-idx3">transconjunctival incisions for, 125</p>
			<p class="endmatter-idx3">transcutaneous incisions for, 124–125, 125<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">vertical eyelid splitting, 125–126</p>
			<p class="endmatter-idx1">Osteomas, 89, 91, 91<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Osteosarcoma, 91</p>
			<p class="endmatter-idx-alpha"><span class="endmatter-idx-alpha_italic">p53</span> mutations, 209</p>
			<p class="endmatter-idx1">Pain, orbital, 21, 133</p>
			<p class="endmatter-idx1">PAN.&#160;<span class="endmatter-idx1_italic">See</span> Polyarteritis nodosa</p>
			<p class="endmatter-idx1">Papillomas, 187</p>
			<p class="endmatter-idx1">Paralytic ectropion, 230<span class="endmatter-idx1_italic">f</span>, 254–255</p>
			<p class="endmatter-idx1">Paranasal sinuses. <span class="endmatter-idx1_italic">See also specific sinus</span></p>
			<p class="endmatter-idx2">adenocarcinoma of, 102, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">anatomy of, 6, 19<span class="endmatter-idx2_italic">f</span>, 19–20</p>
			<p class="endmatter-idx2">development of, 19–20</p>
			<p class="endmatter-idx2">squamous cell carcinoma of, 102, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">tumors from, 101–104, 102–103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Parasitic diseases, 53</p>
			<p class="endmatter-idx1">Parinaud syndrome, 253</p>
			<p class="endmatter-idx1">PD-1. <span class="endmatter-idx1_italic">See</span> Programmed death 1</p>
			<p class="endmatter-idx1">Peginterferon alfa-2b, 210</p>
			<p class="endmatter-idx1">Pembrolizumab, 210</p>
			<p class="endmatter-idx1">Periorbita, 11</p>
			<p class="endmatter-idx1">Periorbital area</p>
			<p class="endmatter-idx2">involutional changes in, 259</p>
			<p class="endmatter-idx2">orbital disorder–related changes in, 22, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">sebaceous carcinoma of, 208</p>
			<p class="endmatter-idx2">sensory innervation of, 18<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">structures of, 19–20</p>
			<p class="endmatter-idx1">Peripheral arterial arcade, 171</p>
			<p class="endmatter-idx1">Peripheral surgical space, 12</p>
			<p class="endmatter-idx1">Peutz-&#173;Jeghers syndrome, 197</p>
			<p class="endmatter-idx1">Phleboliths, 75</p>
			<p class="endmatter-idx1">Phycomycosis, 51</p>
			<p class="endmatter-idx1">Pilar cyst, 189</p>
			<p class="endmatter-idx1">Pilomatricoma (pilomatrixoma), 194, 195<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Pinch technique, 261</p>
			<p class="endmatter-idx1">Pituitary fossa, 8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Pixie-&#173;ear deformity, 274</p>
			<p class="endmatter-idx1">Plasma cell tumors, 95</p>
			<p class="endmatter-idx1">Platysma muscle, 267</p>
			<p class="endmatter-idx1">Platysmaplasty, 276, 276<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Pleomorphic adenomas, 98–100, 99<span class="endmatter-idx1_italic">f</span>, 192</p>
			<p class="endmatter-idx1">Pleomorphic rhabdomyosarcomas, 88</p>
			<p class="endmatter-idx1">Plexiform neurofibromas, 83</p>
			<p class="endmatter-idx1">Polyarteritis nodosa (PAN), 65</p>
			<p class="endmatter-idx1">Porous implants, 139</p>
			<p class="endmatter-idx1">Posterior ethmoidal artery, 9</p>
			<p class="endmatter-idx1">Posterior ethmoidal foramen, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Posterior lamellar deficiency, 254</p>
			<p class="endmatter-idx1">Premalignant epidermal lesions, <br />198–199, 199<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Preseptal cellulitis, 43–46, 44<span class="endmatter-idx1_italic">t</span></p>
			<p class="endmatter-idx1">Pretibial myxedema, 58</p>
			<p class="endmatter-idx1">Pretrichial brow-&#173; and forehead-&#173;lift, 265<span class="endmatter-idx1_italic">f</span>, 265–266</p>
			<p class="endmatter-idx1">Primary anophthalmia, 35</p>
			<p class="endmatter-idx1">Primary orbital meningiomas, 85</p>
			<p class="endmatter-idx1">Probing, for congenital nasolacrimal duct obstruction, 289, 291<span class="endmatter-idx1_italic">f</span>, 291–292, 298, 300</p>
			<p class="endmatter-idx1">Programmed death 1 (PD-1), 206, 211</p>
			<p class="endmatter-idx1">Proptosis</p>
			<p class="endmatter-idx2">computed tomography of, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">definition of, 23–24</p>
			<p class="endmatter-idx2">distensible venous malformations as cause of, 75<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">magnetic resonance imaging of, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pulsatile, 83</p>
			<p class="endmatter-idx1">Prostate cancer, metastatic, 105<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Prostate carcinoma, metastatic, 107</p>
			<p class="endmatter-idx1">Prostheses, ocular, 140–141, 147<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Proton density, 28</p>
			<p class="endmatter-idx1">Pseudoepiphora, 296</p>
			<p class="endmatter-idx1">Pseudoepitheliomatous hyperplasia, 188</p>
			<p class="endmatter-idx1">Pseudoproptosis, 24–25</p>
			<p class="endmatter-idx1">Pseudoptosis, 248–249, 249<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Pseudostrabismus, 177</p>
			<p class="endmatter-idx1">Pterygopalatine fossa, 8, 8<span class="endmatter-idx1_italic">f</span>, 10</p>
			<p class="endmatter-idx1">Ptosis. <span class="endmatter-idx1_italic">See also</span> Brow ptosis</p>
			<p class="endmatter-idx2">anophthalmic, 145, 145<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">aponeurotic, 245, 245<span class="endmatter-idx2_italic">t</span>, 245<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">classification of, 240, 244–252</p>
			<p class="endmatter-idx2">congenital myogenic, 244, 244<span class="endmatter-idx2_italic">f</span>, 245<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">definition of, 240</p>
			<p class="endmatter-idx2">in downgaze, 243</p>
			<p class="endmatter-idx2">evaluation of</p>
			<p class="endmatter-idx3">ancillary testing, 243–244</p>
			<p class="endmatter-idx3">assessments, 242–243</p>
			<p class="endmatter-idx3">eyelid mea&#173;sure&#173;ments, 241–242, 241–242<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">visual field testing in, 243</p>
			<p class="endmatter-idx2">eyelash, 145<span class="endmatter-idx2_italic">f</span>, 184, 185<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">Marcus Gunn jaw-&#173;winking, 243, 246, 247<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">mechanical, 248, 248<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">myogenic, 240, 244<span class="endmatter-idx2_italic">f</span>, 244–245</p>
			<p class="endmatter-idx2">neurogenic</p>
			<p class="endmatter-idx3">acquired, 246–248</p>
			<p class="endmatter-idx3">congenital, 246</p>
			<p class="endmatter-idx3">myasthenia gravis as cause of, 247–248</p>
			<p class="endmatter-idx3">temporary, 247</p>
			<p class="endmatter-idx2">pseudoptosis, 248–249, 249<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">reverse, 246</p>
			<p class="endmatter-idx2">surgical repair of</p>
			<p class="endmatter-idx3">allogenic slings, 252</p>
			<p class="endmatter-idx3">autogenous tensor fascia lata, 252</p>
			<p class="endmatter-idx3">complications of, 252</p>
			<p class="endmatter-idx3">considerations before, 249</p>
			<p class="endmatter-idx3">external levator advancement surgery, <br />249–250, 250<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">Fasanella-&#173;Servat procedure, 250</p>
			<p class="endmatter-idx3">frontalis suspension surgery, 250, 251<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">internal (transconjunctival) approach, 250, <br />251<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">M<span class="endmatter-idx3_accent">ü</span>ller muscle–&#173;conjunctival resection, 250</p>
			<p class="endmatter-idx2">traumatic, 248</p>
			<p class="endmatter-idx1">Pulsating exophthalmos, 112</p>
			<p class="endmatter-idx1">Pulsation of eye, 25</p>
			<p class="endmatter-idx1">Puncta, lacrimal</p>
			<p class="endmatter-idx2">agenesis of, 288</p>
			<p class="endmatter-idx2">anatomy of, 281, 284<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">aplasia, 287, 287<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dilatation of, 291<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">disorders of, 300–302</p>
			<p class="endmatter-idx2">duplication of, 286</p>
			<p class="endmatter-idx2">dysgenesis of, 288</p>
			<p class="endmatter-idx2">epiphora, 301, 301<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">occlusion of, 300</p>
			<p class="endmatter-idx2">plugs, 302, 306, 310</p>
			<p class="endmatter-idx2">stenosis of, 301</p>
			<p class="endmatter-idx2">thermal obliteration of, 311</p>
			<p class="endmatter-idx1">Punctoplasty, 301–302</p>
			<p class="endmatter-idx1">Pupillary examination, in ptosis evaluation, 243</p>
			<p class="endmatter-idx1">Pyogenic granulomas, 142<span class="endmatter-idx1_italic">f</span>, 310–312</p>
			<p class="endmatter-idx-alpha">Quadripod fractures. <span class="endmatter-idx-alpha_italic">See</span> Zygomaticomaxillary complex (ZMC) fractures</p>
			<p class="endmatter-idx-alpha">Radiation therapy</p>
			<p class="endmatter-idx2">basal cell carcinoma treated with, 205</p>
			<p class="endmatter-idx2">complications of, 205</p>
			<p class="endmatter-idx2">infantile hemangiomas treated with, 72</p>
			<p class="endmatter-idx2">lacrimal drainage system tumors treated with, 317</p>
			<p class="endmatter-idx2">malignant lacrimal gland tumors treated with, 100</p>
			<p class="endmatter-idx2">optic nerve glioma treated with, 83</p>
			<p class="endmatter-idx2">rhabdomyosarcomas treated with, 88–89</p>
			<p class="endmatter-idx1">Radioactive iodine</p>
			<p class="endmatter-idx2">hyperthyroidism treated with, 60</p>
			<p class="endmatter-idx2">nasolacrimal duct obstruction caused by, 307</p>
			<p class="endmatter-idx1">Radiofrequency ablation, for trichiasis, 240</p>
			<p class="endmatter-idx1">Reactive lymphoid hyperplasia, 94</p>
			<p class="endmatter-idx1">Reconstructive surgery. <span class="endmatter-idx1_italic">See</span> Eyelid reconstruction</p>
			<p class="endmatter-idx1">Reflex blepharospasm, 256</p>
			<p class="endmatter-idx1">Rejuvenation, facial</p>
			<p class="endmatter-idx2">autologous fat grafting for, 271</p>
			<p class="endmatter-idx2">botulinum toxin for, 269–270</p>
			<p class="endmatter-idx2">dermal fillers for, 270<span class="endmatter-idx2_italic">f</span>, 270–271</p>
			<p class="endmatter-idx2">hyaluronic acid fillers for, 270, 270<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">&#173;laser skin resurfacing for, 268–269</p>
			<p class="endmatter-idx2">lower face, 272–273</p>
			<p class="endmatter-idx2">nonsurgical, 268–271, 270<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">rhytidectomy, 273–274, 274–275<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">soft-&#173;tissue dermal fillers for, 270<span class="endmatter-idx2_italic">f</span>, 270–271</p>
			<p class="endmatter-idx2">surgical techniques for, 271–276, 272–275<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Retinoblastoma, 136</p>
			<p class="endmatter-idx1">Retro-&#173;orbicularis oculi fat (ROOF), 168</p>
			<p class="endmatter-idx1">Retrobulbar block, 13</p>
			<p class="endmatter-idx1">Retrocaruncular incision</p>
			<p class="endmatter-idx2">for medial orbitotomy, 128, 128<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">for orbital decompression, 130</p>
			<p class="endmatter-idx1">Reverse ptosis, 246</p>
			<p class="endmatter-idx1">Revised European-&#173;American Lymphoma <br />Classification, 91</p>
			<p class="endmatter-idx1">Rhabdomyosarcoma, 87<span class="endmatter-idx1_italic">f</span>, 87–89</p>
			<p class="endmatter-idx1">Rhomboid flaps, for lateral canthal defects, 225, 226<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Rhytidectomy, 273–274, 274–275<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Rituximab, 61, 67</p>
			<p class="endmatter-idx1">ROOF. <span class="endmatter-idx1_italic">See</span> Retro-&#173;orbicularis oculi fat</p>
			<p class="endmatter-idx1">Rotation flaps, for lower eyelid defects, 224</p>
			<p class="endmatter-idx1">Rotational upper eyelid pedicle flap, 227<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Rundle’s curve, 58, 58<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Sagittal plane, 27</p>
			<p class="endmatter-idx1">Salmon-&#173;patch subconjunctival lesion, 94<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Sarcoidosis, 65<span class="endmatter-idx1_italic">f</span>, 65–66</p>
			<p class="endmatter-idx1">SCC. <span class="endmatter-idx1_italic">See</span> Squamous cell carcinoma</p>
			<p class="endmatter-idx1">Scleritis, 68</p>
			<p class="endmatter-idx1">Sclerosants</p>
			<p class="endmatter-idx2">for distensible venous malformations, 75</p>
			<p class="endmatter-idx2">for lymphatic malformations, 74</p>
			<p class="endmatter-idx1">Sclerosing nonspecific orbital inflammation, 70</p>
			<p class="endmatter-idx1">Sebaceous adenoma, 191</p>
			<p class="endmatter-idx1">Sebaceous carcinoma, 206–208, 207<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Sebaceous cysts, 189</p>
			<p class="endmatter-idx1">Sebaceous hyperplasia, 191</p>
			<p class="endmatter-idx1">Seborrheic keratosis, 187–188, 188, 188<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Sebum, 182</p>
			<p class="endmatter-idx1">Secondary anophthalmia, 35</p>
			<p class="endmatter-idx1">Segmental trichiasis, 240</p>
			<p class="endmatter-idx1">Selenium supplementation, in thyroid eye disease, 59</p>
			<p class="endmatter-idx1">Semicircular advancement flaps, for lower eyelid defects, 224</p>
			<p class="endmatter-idx1">Semicircular flap, for lower eyelid defects, 223<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Senile lentigo, 197</p>
			<p class="endmatter-idx1">Sentinel lymph node biopsy</p>
			<p class="endmatter-idx2">for melanoma, 210</p>
			<p class="endmatter-idx2">for sebaceous carcinoma, 208</p>
			<p class="endmatter-idx1">Short posterior ciliary nerves, 12<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">&#173;Silent sinus syndrome, 102, 103<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Silicone rods, in frontalis suspension surgery, <br />251<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Sino-&#173;orbital zygomycosis, 51<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Sinusitis</p>
			<p class="endmatter-idx2">in ethmoid sinus, 20</p>
			<p class="endmatter-idx2">orbital cellulitis and, 46</p>
			<p class="endmatter-idx2">sinus surgery for, 47</p>
			<p class="endmatter-idx1">Skin</p>
			<p class="endmatter-idx2">Fitzpatrick scale for, 268</p>
			<p class="endmatter-idx2">&#173;laser resurfacing of, 268–269</p>
			<p class="endmatter-idx1">Skin cancer</p>
			<p class="endmatter-idx2">predisposing &#173;factors for, 186</p>
			<p class="endmatter-idx2">signs of, 187</p>
			<p class="endmatter-idx1">SMAS. <span class="endmatter-idx1_italic">See</span> Superficial musculoaponeurotic <br />system</p>
			<p class="endmatter-idx1">Smoking cessation, in thyroid eye disease, 59</p>
			<p class="endmatter-idx1">Snapback test, 231, 260</p>
			<p class="endmatter-idx1">Soft-&#173;tissue dermal fillers, 157, 270<span class="endmatter-idx1_italic">f</span>, 270–271</p>
			<p class="endmatter-idx1">Solar lentigo, 197–198, 198<span class="endmatter-idx1_italic">f</span>, 200</p>
			<p class="endmatter-idx1">Solitary fibrous tumor, 89, 90<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Sonidegib, 205</p>
			<p class="endmatter-idx1">SOOF. <span class="endmatter-idx1_italic">See</span> Suborbicularis oculi fat</p>
			<p class="endmatter-idx1">SPAs. <span class="endmatter-idx1_italic">See</span> Subperiosteal abscesses</p>
			<p class="endmatter-idx1">Spastic entropion, 235<span class="endmatter-idx1_italic">f</span>, 237</p>
			<p class="endmatter-idx1">Sphenoethmoidal recess, 19, 20</p>
			<p class="endmatter-idx1">Sphenoid bone</p>
			<p class="endmatter-idx2">greater wing of, 7–8<span class="endmatter-idx2_italic">f</span>, 9</p>
			<p class="endmatter-idx2">lesser wing of, 7–8<span class="endmatter-idx2_italic">f</span>, 9, 11</p>
			<p class="endmatter-idx2">metastatic tumors of, 105</p>
			<p class="endmatter-idx1">Sphenoid sinus</p>
			<p class="endmatter-idx2">anatomy of, 8<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">development of, 20</p>
			<p class="endmatter-idx1">Sphenoid wing meningiomas, 84<span class="endmatter-idx1_italic">f</span>, 84–86</p>
			<p class="endmatter-idx1">Spiral CT scanners, 27</p>
			<p class="endmatter-idx1">Squamous cell carcinoma (SCC)</p>
			<p class="endmatter-idx2">actinic keratosis as cause of, 199</p>
			<p class="endmatter-idx2">of ethmoid sinus, 102, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">of eyelid, 205–206, 206<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">of lacrimal sac, 316<span class="endmatter-idx2_italic">f</span>, 317</p>
			<p class="endmatter-idx2">in situ, 199</p>
			<p class="endmatter-idx1">Stab incisions, 274</p>
			<p class="endmatter-idx1">Stents</p>
			<p class="endmatter-idx2">bicanalicular lacrimal, 293, 294<span class="endmatter-idx2_italic">f</span>, 301<span class="endmatter-idx2_italic">f</span>, 312</p>
			<p class="endmatter-idx2">lacrimal intubation, 292–294, 294<span class="endmatter-idx2_italic">f</span>, 303</p>
			<p class="endmatter-idx1">Stereotactic navigation, 32, 33<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Steroids. <span class="endmatter-idx1_italic">See</span> Corticosteroids</p>
			<p class="endmatter-idx1">Stevens-&#173;Johnson syndrome, 237, 238<span class="endmatter-idx1_italic">f</span>, 303</p>
			<p class="endmatter-idx1">Stye. <span class="endmatter-idx1_italic">See</span> Hordeolum</p>
			<p class="endmatter-idx1">Sub-&#173;Tenon surgical space, 124</p>
			<p class="endmatter-idx1">Subarachnoid surgical space, 124</p>
			<p class="endmatter-idx1">Subconjunctival nodules, 65, 65<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Submental liposuction, 275<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Suborbicular fat pads, 168</p>
			<p class="endmatter-idx1">Suborbicularis oculi fat (SOOF)</p>
			<p class="endmatter-idx2">anatomy of, 168</p>
			<p class="endmatter-idx2">lift/elevation of, 224, 272</p>
			<p class="endmatter-idx1">Subperiosteal abscesses (SPAs), 47</p>
			<p class="endmatter-idx1">Subperiosteal fluid, 11</p>
			<p class="endmatter-idx1">Subperiosteal midface-&#173;lift, 272, 273<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Subperiosteal surgical space, 123, 123<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Subtotal exenteration, 146</p>
			<p class="endmatter-idx1">Sump syndrome, 310, 310<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Superficial mimetic muscles, 153</p>
			<p class="endmatter-idx1">Superficial musculoaponeurotic system (SMAS)</p>
			<p class="endmatter-idx2">description of, 151–153, 152<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">rhytidectomy of, 273, 274<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Superior cantholysis, 119, 222<span class="endmatter-idx1_italic">f</span>, 223<span class="endmatter-idx1_italic">f</span>. <span class="endmatter-idx1_italic">See also</span> Cantholysis</p>
			<p class="endmatter-idx1">Superior conchae, 19</p>
			<p class="endmatter-idx1">Superior oblique muscle, 12–13<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Superior oblique tendon, 6</p>
			<p class="endmatter-idx1">Superior ophthalmic vein, 12<span class="endmatter-idx1_italic">f</span>, 14</p>
			<p class="endmatter-idx1">Superior orbital fissure, 6, 7<span class="endmatter-idx1_italic">f</span>, 9, 130<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Superior orbitotomy</p>
			<p class="endmatter-idx2">transconjunctival incisions for, 125</p>
			<p class="endmatter-idx2">transcutaneous incisions for, 124–125, 125<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">vertical eyelid splitting, 125–126</p>
			<p class="endmatter-idx1">Superior rectus muscle, 12, 13<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Superior sulcus deformity, 141<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Supraorbital ethmoids, 20</p>
			<p class="endmatter-idx1">Supraorbital foramen, 6, 7<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Supraorbital notch, 6</p>
			<p class="endmatter-idx1">Surgery. <span class="endmatter-idx1_italic">See also</span> Orbital surgery</p>
			<p class="endmatter-idx2">basal cell carcinoma treated with, 204</p>
			<p class="endmatter-idx2">chalazion treated with, 182–183, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">facial rejuvenation techniques, 271–276, 272–275<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">infantile hemangiomas treated with, 72</p>
			<p class="endmatter-idx2">necrotizing fasciitis treated with, 49<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">optic nerve glioma treated with, 82</p>
			<p class="endmatter-idx2">orbital fractures treated with, 117</p>
			<p class="endmatter-idx2">ptosis treated with. <span class="endmatter-idx2_italic">See</span> Ptosis, surgical repair of</p>
			<p class="endmatter-idx1">Surgical myectomy, 257–258</p>
			<p class="endmatter-idx1">Symblepharon, 239</p>
			<p class="endmatter-idx1">Sympathetic ophthalmia, 136–138</p>
			<p class="endmatter-idx1">Syndromic craniosynostosis, 39, 39<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Synkinesis, 243, 246</p>
			<p class="endmatter-idx1">Syringomas, 192, 192<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">T-&#173;VEC.&#160;<span class="endmatter-idx-alpha_italic">See</span> Laherparepvec</p>
			<p class="endmatter-idx1">T1-&#173;weighted magnetic resonance imaging, 28<span class="endmatter-idx1_italic">f</span>, 30<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">T2-&#173;weighted magnetic resonance imaging, 28<span class="endmatter-idx1_italic">f</span>, 30<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">T<span class="endmatter-idx1_subscript _idGenCharOverride-1">3</span>. See Triiodothyronine</p>
			<p class="endmatter-idx1">T<span class="endmatter-idx1_subscript _idGenCharOverride-1">4</span>. See Thyroxine</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Taenia solium,</span> 53</p>
			<p class="endmatter-idx1">Tarsal ectropion, 232</p>
			<p class="endmatter-idx1">Tarsal fracture operation, 237, 238<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Tarsal kink, 179, 179<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Tarsal strip procedure. <span class="endmatter-idx1_italic">See</span> Lateral tarsal strip <br />procedure</p>
			<p class="endmatter-idx1">Tarsoconjunctival flaps</p>
			<p class="endmatter-idx2">description of, 218</p>
			<p class="endmatter-idx2">lower eyelid defects reconstructed with, 223<span class="endmatter-idx2_italic">f</span>, 224</p>
			<p class="endmatter-idx1">Tarsoconjunctival graft, 221</p>
			<p class="endmatter-idx1">Tarsorrhaphy, 255, 255<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Tarsus, 168, 169<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">TBII test. <span class="endmatter-idx1_italic">See</span> Thyrotropin-&#173;binding inhibitory immunoglobulin (TBII) test</p>
			<p class="endmatter-idx1">Tear breakup time, 296</p>
			<p class="endmatter-idx1">Tear film, 280–281</p>
			<p class="endmatter-idx1">Tear meniscus, 296</p>
			<p class="endmatter-idx1">Tearing. <span class="endmatter-idx1_italic">See</span> Epiphora</p>
			<p class="endmatter-idx1">TED.&#160;<span class="endmatter-idx1_italic">See</span> Thyroid eye disease</p>
			<p class="endmatter-idx1">Telecanthus, 23, 169, 169<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Telorbitism, 23</p>
			<p class="endmatter-idx1">Temporal arteritis. <span class="endmatter-idx1_italic">See</span> &#173;Giant cell arteritis</p>
			<p class="endmatter-idx1">Temporal flare, 253</p>
			<p class="endmatter-idx1">Temporalis muscle, 152<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">“Temporary tarsorrhaphy,” 255</p>
			<p class="endmatter-idx1">Temporoparietal fascia, 151, 153</p>
			<p class="endmatter-idx1">Teprotumumab, 61</p>
			<p class="endmatter-idx1">Teratoma, 42</p>
			<p class="endmatter-idx1">Tetracycline, for chalazion, 182</p>
			<p class="endmatter-idx1">Third-&#173;order neuron dysfunction, 243–244</p>
			<p class="endmatter-idx1">Three-&#173;dimensional CT, 27, 27<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">3-&#173;dimensional navigation, 33<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Thyroid-&#173;associated orbitopathy. <span class="endmatter-idx1_italic">See</span> Thyroid eye <br />disease</p>
			<p class="endmatter-idx1">Thyroid eye disease (TED)</p>
			<p class="endmatter-idx2">asymmetric, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">autoimmune hyperthyroidism associated with, 57</p>
			<p class="endmatter-idx2">Clinical Activity Score for, 58</p>
			<p class="endmatter-idx2">clinical features of, 57–58</p>
			<p class="endmatter-idx2">clinical signs of, 53–54, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">compressive optic neuropathy associated with, <br />60–61</p>
			<p class="endmatter-idx2">description of, 24–25, 53–54</p>
			<p class="endmatter-idx2">diagnosis of, 55–56</p>
			<p class="endmatter-idx2">diplopia associated with, 61–62</p>
			<p class="endmatter-idx2">epidemiology of, 57</p>
			<p class="endmatter-idx2">eyelid retraction caused by, 253</p>
			<p class="endmatter-idx2">glucocorticoids for, 60–61</p>
			<p class="endmatter-idx2">hyperthyroidism and, 60</p>
			<p class="endmatter-idx2">key points about, 55</p>
			<p class="endmatter-idx2">orbital decompression for, 130, 131<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">pathogenesis of, 57</p>
			<p class="endmatter-idx2">pretibial myxedema associated with, 58</p>
			<p class="endmatter-idx2">prognosis for, 58–62</p>
			<p class="endmatter-idx2">radiographic evidence of, 55, 56<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">radiotherapy for, 61</p>
			<p class="endmatter-idx2">rituximab for, 61</p>
			<p class="endmatter-idx2">selenium supplementation in, 59</p>
			<p class="endmatter-idx2">serologic testing for, 56</p>
			<p class="endmatter-idx2">smoking cessation in, 59</p>
			<p class="endmatter-idx2">surgery for, 61–62</p>
			<p class="endmatter-idx2">treatment of, 58–62, 60<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx2">upper eyelid retraction associated with, 58</p>
			<p class="endmatter-idx1">Thyroid-&#173;stimulating hormone (TSH), 34, 56</p>
			<p class="endmatter-idx1">Thyrotropin-&#173;binding inhibitory immunoglobulin (TBII) test, 56</p>
			<p class="endmatter-idx1">Thyroxine (T<span class="endmatter-idx1_subscript _idGenCharOverride-1">4</span>), 55, 56, 60</p>
			<p class="endmatter-idx1">Timolol, for infantile hemangiomas, 72</p>
			<p class="endmatter-idx1">TMP-&#173;SMX.&#160;<span class="endmatter-idx1_italic">See</span> Trimethoprim-&#173;sulfamethoxazole</p>
			<p class="endmatter-idx1">Tocilizumab, 63</p>
			<p class="endmatter-idx1">Total exenteration, 146, 147<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Traction test, 114</p>
			<p class="endmatter-idx1">Tram-&#173;tracking, 86</p>
			<p class="endmatter-idx1">Transconjunctival incisions</p>
			<p class="endmatter-idx2">for inferior orbitotomy, 126–127, 127<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">for medial orbitotomy, 128</p>
			<p class="endmatter-idx2">for superior orbitotomy, 125</p>
			<p class="endmatter-idx1">Transcutaneous incisions</p>
			<p class="endmatter-idx2">for inferior orbitotomy, 126, 126<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">for medial orbitotomy, 128</p>
			<p class="endmatter-idx2">for superior orbitotomy, 125</p>
			<p class="endmatter-idx1">Trauma</p>
			<p class="endmatter-idx2">canalicular, 311–312</p>
			<p class="endmatter-idx2">canthal tendon, 214–215</p>
			<p class="endmatter-idx2">eyelid. <span class="endmatter-idx2_italic">See</span> Eyelid trauma</p>
			<p class="endmatter-idx2">lacrimal sac, 312</p>
			<p class="endmatter-idx2">nasolacrimal duct, 312</p>
			<p class="endmatter-idx2">nasolacrimal duct obstruction caused by, <br />306</p>
			<p class="endmatter-idx2">orbital. <span class="endmatter-idx2_italic">See</span> Orbital trauma</p>
			<p class="endmatter-idx1">Traumatic optic neuropathy, 119, 121<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Traumatic ptosis, 248</p>
			<p class="endmatter-idx1">Treacher Collins syndrome, 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Triage, 122</p>
			<p class="endmatter-idx1">Trichiasis, 235, 239<span class="endmatter-idx1_italic">f</span>, 239–240</p>
			<p class="endmatter-idx1">Trichilemmal cyst, 189</p>
			<p class="endmatter-idx1">Trichilemmoma, 194</p>
			<p class="endmatter-idx1"><span class="endmatter-idx1_italic">Trichinella spiralis,</span> 53</p>
			<p class="endmatter-idx1">Trichinosis, 53</p>
			<p class="endmatter-idx1">Trichoepithelioma, 193, 194<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Trichofolliculoma, 193, 194<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Trichotillomania, 186, 186<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Trigeminal ganglion, 14</p>
			<p class="endmatter-idx1">Trigeminal nerve</p>
			<p class="endmatter-idx2">divisions of, 9–10, 14</p>
			<p class="endmatter-idx2">efferent pathway of, 280</p>
			<p class="endmatter-idx2">maxillary division of, 14</p>
			<p class="endmatter-idx2">nasociliary branch of, 13</p>
			<p class="endmatter-idx2">ophthalmic division of, 14</p>
			<p class="endmatter-idx1">Triiodothyronine (T<span class="endmatter-idx1_subscript _idGenCharOverride-1">3</span>), 55, 56</p>
			<p class="endmatter-idx1">Trimethoprim-sulfamethoxazole (TMP-SMX)</p>
			<p class="endmatter-idx2">for cellulitis, 45</p>
			<p class="endmatter-idx2">for granulomatosis with polyangiitis, 64</p>
			<p class="endmatter-idx1">Trochlear nerve, 13</p>
			<p class="endmatter-idx1">TSH.&#160;<span class="endmatter-idx1_italic">See</span> Thyroid-&#173;stimulating hormone</p>
			<p class="endmatter-idx1">Tumors. <span class="endmatter-idx1_italic">See</span> Eyelid neoplasms and tumors; Lacrimal gland, tumors of; Mesenchymal tumors; Metastatic tumors; Orbital tumors</p>
			<p class="endmatter-idx1">Turban tumors, 193</p>
			<p class="endmatter-idx1">Turbinates</p>
			<p class="endmatter-idx2">anatomy of, 19</p>
			<p class="endmatter-idx2">infracture of, 294</p>
			<p class="endmatter-idx-alpha">Ultrasonography</p>
			<p class="endmatter-idx2">A-&#173;scan, 31</p>
			<p class="endmatter-idx2">B-&#173;scan, 31</p>
			<p class="endmatter-idx2">Doppler, 31</p>
			<p class="endmatter-idx2">orbital disorders evaluated using, 31</p>
			<p class="endmatter-idx2">orbital foreign bodies on, 117</p>
			<p class="endmatter-idx1">Upper eyelids. <span class="endmatter-idx1_italic">See also</span> Eyelid(s); <span class="endmatter-idx1_italic">specific disorders</span></p>
			<p class="endmatter-idx2">anatomy of, 160<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">anophthalmic ptosis of, 145<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">blepharoplasty of</p>
			<p class="endmatter-idx3">brow ptosis and, 264</p>
			<p class="endmatter-idx3">description of, 259</p>
			<p class="endmatter-idx3">preoperative evaluation, 260</p>
			<p class="endmatter-idx3">retraction caused by, 253<span class="endmatter-idx3_italic">f</span>, 254</p>
			<p class="endmatter-idx3">technique for, 261, 261<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx2">crease incision of, 125, 165</p>
			<p class="endmatter-idx2">crease of, 160, 242, 244</p>
			<p class="endmatter-idx2">defects involving, reconstruction of, 220–221, 222<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">dermatochalasis of, 259</p>
			<p class="endmatter-idx2">entropion of, 234</p>
			<p class="endmatter-idx2">eversion of, 174, 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">excursion of, 242</p>
			<p class="endmatter-idx2">fold of, 160–161</p>
			<p class="endmatter-idx2">laceration of, 214<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">mea&#173;sure&#173;ments of, 242</p>
			<p class="endmatter-idx2">milia of, 189, 189<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">orbital septum, 163</p>
			<p class="endmatter-idx2">paralysis of, 255–256</p>
			<p class="endmatter-idx2">ptosis of, 240</p>
			<p class="endmatter-idx2">retraction of</p>
			<p class="endmatter-idx3">clinical features of, 253, 254<span class="endmatter-idx3_italic">f</span></p>
			<p class="endmatter-idx3">in thyroid eye disease, 58</p>
			<p class="endmatter-idx2">trichiasis of, 239<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">vertical splitting of, 125–126</p>
			<p class="endmatter-idx2">von Graefe sign of, 25</p>
			<p class="endmatter-idx-alpha">Valve of Hasner</p>
			<p class="endmatter-idx2">anatomy of, 283</p>
			<p class="endmatter-idx2">in congenital nasolacrimal duct obstruction, 283, 288–289</p>
			<p class="endmatter-idx1">Valve of Rosenm<span class="endmatter-idx1_accent">ü</span>ller, 281<span class="endmatter-idx1_italic">f</span>, 282, 289, 298</p>
			<p class="endmatter-idx1">Vasculitis</p>
			<p class="endmatter-idx2">&#173;giant cell arteritis, 62–63</p>
			<p class="endmatter-idx2">granulomatosis with polyangiitis, 63–64, 64<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">polyarteritis nodosa, 65</p>
			<p class="endmatter-idx1">Venography, 32</p>
			<p class="endmatter-idx1">Venous malformations</p>
			<p class="endmatter-idx2">cavernous, 75–77, 76<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">combined lymphatic, 74</p>
			<p class="endmatter-idx2">distensible, 74–75, 75<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx1">Verruca vulgaris, 188, 188<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Vertical palpebral fissure, 242</p>
			<p class="endmatter-idx1">VISA inflammatory scoring system, <br />58, 59<span class="endmatter-idx1_italic">t</span></p>
			<p class="endmatter-idx1">Vision loss</p>
			<p class="endmatter-idx2">orbital surgery as cause of, 133</p>
			<p class="endmatter-idx2">traumatic, with clear media, 119, 121</p>
			<p class="endmatter-idx1">Vismodegib, 205</p>
			<p class="endmatter-idx1">Visual field testing, 243</p>
			<p class="endmatter-idx1">von Graefe sign, 25</p>
			<p class="endmatter-idx1">von Recklinghausen disease, 83. <span class="endmatter-idx1_italic">See also</span> <br />Neurofibromatosis I</p>
			<p class="endmatter-idx-alpha">Wegener granulomatosis. <span class="endmatter-idx-alpha_italic">See</span> Granulomatosis with polyangiitis</p>
			<p class="endmatter-idx1">Whitnall ligament, 6, 164–166, 166<span class="endmatter-idx1_italic">f</span>, 279</p>
			<p class="endmatter-idx1">Whitnall tubercle, 279</p>
			<p class="endmatter-idx1">Worm’s-&#173;eye view, 24, 25<span class="endmatter-idx1_italic">f</span>, 102<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Xanthelasmas, 190, 190<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="endmatter-idx1">Xanthogranuloma, 97</p>
			<p class="endmatter-idx1">Xeroderma pigmentosum, 202, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Y–&#173;V-&#173;plasty</p>
			<p class="endmatter-idx2">for blepharophimosis–&#173;ptosis–&#173;epicanthus inversus syndrome, 174, 175<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx2">for epicanthus tarsalis, 177, 178<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx-alpha">Z-&#173;plasties, for blepharophimosis–&#173;ptosis–&#173;epicanthus inversus syndrome, 174, 175<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="endmatter-idx1">ZMC fractures. <span class="endmatter-idx1_italic">See</span> Zygomaticomaxillary complex (ZMC) fractures</p>
			<p class="endmatter-idx1">Zygomatic bone, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Zygomatic fractures, 109, 111, 111<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Zygomaticofacial canal, 10</p>
			<p class="endmatter-idx1">Zygomaticofacial foramen, 7–8<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Zygomaticomaxillary complex (ZMC) fractures, 109, 111, 111<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Zygomaticotemporal canal, 10</p>
			<p class="endmatter-idx1">Zygomaticotemporal foramen, 7<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx1">Zygomycetes, 51</p>
			<p class="endmatter-idx1">Zygomycosis, 51–52</p>
		</div>
	</body>
</html>
